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1. Summary 
Inhibitors targeting KRAS proto-oncogene GTPase do not compare favorably with other drugs 
and have so far failed in clinical trials. Based on these facts, KRAS is seen as undruggable. 
However, with a mutation incidence of 30-40% of all human cancers, KRAS is still considered 
an attractive pan-cancer target. To shed light on this major clinical problem, we treated a panel 
of murine and human tumor cells with KRAS drugs deltarasin (inhibiting transport protein 
phosphodiesterase-δ), cysmethynil (inhibiting isoprenylcysteine carboxylmethyltransferase), 
and AA12 (allosterically inhibiting mutant KRASG12C isoform). Additionally, we overexpressed 
or silenced mutant KRAS using gene modification techniques. We show an exclusively in vivo 
effect of Kras/KRAS mutant cancer cells to genetic and pharmacologic KRAS blockade. We 
demonstrate that the hyperactive GTPase uses host myeloid cells via a C-C motif chemokine 
ligand 2 (CCL2)/ interleukin-1β (IL-1β)-mediated signaling loop for constant tumorigenicity. 
Certainly, tumors harboring mutated Kras/KRAS did respond less to daily deltarasin treatment 
in Ccr2 and Il1b gene-deficient mice while being drug-sensitive in wild-type (WT) mice. Similar 
findings were achieved with adoptive bone marrow transplant (BMT) experiments of Ccr2-
deficient mice receiving WT bone marrow. Deltarasin treatment suppressed interleukin-1 
receptor 1 (IL1R1) expression and myeloid IL-1β-initiated pro-growth effects in vivo. With this 
we provide a novel mechanism of how mutant KRAS functions to promote tumorigenesis 
beyond the confines of the cancer cell. Our murine KRAS dependent pro-inflammatory gene 
expression signature showed strong parallels with KRAS mutant human cancers and predicted 
poor survival. This work highlights the possibility that CCL2 and IL-1β, as well as their 
respective receptors are important targets to consider in the search for treating KRAS mutant 
cancer patients. In particular, IL-1β blockade can be a strategy suitable for this therapy which 
might provide mechanistic insights on recent findings on IL-1β blockade and lung cancer 
incidence in the CANTOS (Canakinumab anti-inflammatory thrombosis outcome study) trial. 
In addition, the findings imply that traditional methods employed for drug screens are 
inaccurate for the development of anti-KRAS compound screens since the essential drug 
function needs to address the inflammatory tumor microenvironment. This is in line with others, 
believing in a discrepancy between in vitro and in vivo findings related to KRAS inhibition.  
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2. Zusammenfassung  
KRAS (Proto-Oncogene GTPase) ist eines der häufigsten Onkogene und kommt in soliden 
Tumoren vor, allen voran Pankreas-, Darm- und Lungenkrebs. Obwohl es eine extrem wichtige 
Stellung hat, gibt es noch keine zielgerichteten Therapeutika. Bis jetzt stellt die Mutation 
maximal einen indirekten Angriffspunkt für Medikamente dar und einen Biomarker für Primär- 
und Sekundärresistenzen von klinischen EGFR-Inhibitoren. Eine Vielzahl von Versuchen 
wurde unternommen, um KRAS Inhibitoren zu entwickeln, teilweise auch in klinischen Studien, 
ohne Erfolg. Um dieses medizinische Problem besser zu verstehen, wurden hier in vitro und 
in vivo Versuche in humanen und murinen Zelllinien mit den KRAS Inhibitoren Deltarasin, 
Cysmethynil und AA12 verglichen und entscheidende Unterschiede festgestellt. Diese zeigten 
uns, dass deren Wirkung in vitro unabhängig von dem Vorliegen der Mutation eintritt. Im 
Vergleich dazu zeigte der KRAS Inhibitor Deltarasin in Mausmodellen eine spezifisch 
wirksame Verlangsamung des Tumorwachstums. Das Gleiche wurde parallel an genetisch 
veränderten Zelllinien durchgeführt mit entsprechendem Ergebnis. Im weiteren Verlauf 
konnten wir diese Unterschiede einer KRAS regulierten Immunantwort zuordnen, bei der 
CCR2+ myeloide Zellen durch C-C Motif Chemokine Ligand 2 (CCL2) - Sekretion rekrutiert 
werden und diese Interleukin-1β (IL-1β) ausschütten. Die Interleukin-Sekretion bewirkt ein 
aggressiveres Wachstum KRAS mutierter Tumore. Diese Signalkaskade konnte mit 
geeigneten Knockout- sowie Knochenmark-Transplantations- Mausmodellen bewiesen 
werden. Der KRAS Inhibitor Deltarasin greift in diesen Mechanismus ein. Wir konnten zeigen, 
dass der Wirkstoff die Expression von IL-1R1 minimiert. Durch Transkriptomanalyse filterten 
wir eine Kras-spezifische Liste von Genen heraus, die inflammatorische Mediatoren enthält, 
unter anderem Il1r1 und Ccl2. Diese Daten spielten auch im humanen, molekularen 
Krankheitsprofil eine Rolle. So präsentiert diese Arbeit innovative, klinisch relevante 
Angriffspunkte für die Behandlung von Lungenkrebs mit vorliegender KRAS Mutation: Die 
Mediatoren CCL2 und IL-1β, sowie deren Rezeptoren. Außerdem wird deutlich, dass 
konservative Screening-Methoden nicht das Mittel der Wahl sind, um KRAS Inhibitoren zu 
entwickeln, da die Immunantwort dabei außer Acht gelassen wird.    
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3. Introduction 
 Lung cancer – an overview 
 Epidemiology 
Cancer is the second reason for death nowadays behind cardiovascular diseases (Fig. 1A). 
Lung cancer (LC) is the global number one occurring cancer type with increasing incidence 
rates and an estimation of 2.09 Mio new cases in 20181. It is also the leading cause of cancer 
related deaths gender independent and worldwide (Fig. 1B)1,2. A geographical difference is 
evident depending on smoking habits, indoor and outdoor air pollution, tobacco taxes, and 
anti-smoking policies of countries like USA or Europe in contrast to China and Asia. In South 
Africa, price per package had quadrupled over ten years and consumption thereby has 
halved3. On the other side, China with increasing smoker numbers, consuming one-third of all 
cigarettes smoked globally and with China the world’s main tobacco producer1. This will 
increase in the next years and visualizes a shift in the worldwide lung cancer burden from high-
income to low- and middle-income countries, predominantly Asia4. General incidence and 
mortality rates are still similar (Fig. 1B) since early diagnosis is not given yet and therapy 
options are limited. Men have a higher risk of developing lung cancer then women (Fig. 1B). 
Main risk factor is smoking being the reason for over 90% of new lung cancer cases. This 
includes exposure to passive cigarette smoking. Other harmful factors are agents like 
asbestos, arsenic, nickel, and chromium, radiation, and outdoor and indoor air pollution5. The 
presence of other lung disorders are affecting the incidence rate of lung cancer as well, such 
as fibrotic disorders or COPD1,2.  
3 Introduction 
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Figure 1: Incidence and mortality of diseases and lung cancer. (A) Worldwide causes of death, 2016. 
Figure produced based on numbers of the global burden of disease (GBD) database and available 
online at: https://ourworldindata.org/causes-of-death. Last accessed July 26, 2019. (B) Worldwide lung 
cancer incidence and mortality stratified by sex. Figure from GLOBOCAN made by the International 
Agency for Research on Cancer (IARC) for 2018. Online available at: 
http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Last accessed July 26, 2019. 
 
 Histology and mutational landscape 
LC is classified according to the world health organization (WHO) into two main types, 15% of 
all cases are small cell lung carcinoma (SCLC) and non-SCLC (NSCLC) accounting for the 
rest (85%). NSCLC can be subdivided into aggressive large cell carcinoma (15%), squamous 
cell carcinoma (30%), and lung adenocarcinoma (LADC; 40%) making LADC the most 
3 Introduction 
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common type. It is further divided depending on invasiveness, in detail in situ as preinvasive 
tumor, minimal invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive 
adenocarcinoma classified by size. LADC appears often in the cells lining the alveoli, while 
squamous cell carcinoma appears in the flat cells of the airways near the bronchi. In 2015 the 
WHO established a new category of invasive, neuroendocrine tumors comprising three 
subtypes: large cell neuroendocrine carcinoma (LCNEC), SCLC, and typical or atypical 
carcinoid tumor6.  
The Cancer Genome Atlas (TCGA) is working on identification of genomic and molecular 
alterations for different types of cancer. For LADC a high mutation burden is proven [8.9 
mutations per one million nucleotides (one megabase, Mb)] and common mutations are: TP53 
(46%), KRAS (33%), STK11 (17%), KEAP1 (17%), EGFR (14%), NF1 (11%), BRAF (10%), 
ARID1A (7%), MET (7%), PIK3CA (7%), SMARCA4 (6%), and CDKN2A (4%, see full gene 
names under 9. abbreviations)7. Epidermal growth factor receptor (EGFR), B-Raf proto-
oncogene (BRAF), the rare anaplastic lymphoma kinase (ALK; 1.3%), and ROS proto-
oncogene (ROS1) fusions (1.7%) are clinically used biomarkers. EGFR and KRAS proto-
oncogene GTPase (KRAS) mutations are mutually exclusive, but serine/threonine kinase 11 
(STK11) or tumor protein P53 (TP53) mutations are positively correlated with mutations in 
KRAS8. Moreover, 75% of LADC genetic alterations promote the RTK/RAS/RAF signaling 
pathway, due to driver mutations promoting this signaling pathway. These include KRAS, 
EGFR, and BRAF. Driver mutations are crucial for initiation and progression of tumor growth, 
same in all patients of a specific cancer, and support the cell with a clonal selective advantage. 
Passenger mutations are more random and occur often through drug resistance development, 
but mainly prior to the driver mutation. They can also transform into drivers, then called latent 
driver mutations9. Both loss-of-function mutations in tumorsupressors and gain-of-function 
mutations in oncogenes work together to change the normal growth of cells to an abnormal 
pathological network effecting cell proliferation, cell cycle, repair mechanisms, control of 
transcription and protein expression, etc. (Fig. 2)7.  
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Figure 2: The cancer genome atlas research network (TCGA) analyzed the molecular profile of lung 
tumor and matched healthy tissue of 230 lung cancer patients. (Left) Main driver mutations are found to 
be involved in RTK/RAS/RAF signaling to 75%. (Right) Main tumorsupressors (blue) and oncogenes 
(red) of LADC are involved in variant signaling pathways such as proliferation, cell survival, cell cycle 
progression, oxidative stress response, and nucleosome remodeling. Figures from TCGA publication 
2014 analyzing 230 LADC patient samples on DNA, RNA, and protein level7.  
 
 Current staging and treatment  
General age of diagnosis is 68 to 70 years and usually too late, since early diagnosis via 
computer-tomography (CT) is no routine yet and could help especially the at-risk group of 
smokers. Nowadays patient groups will be classified by multiple variants like genotype, age, 
sex, histology, stage, comorbidity, and fitness. Therapy options depend on progression of 
cancer and are surgery, chemotherapy, radiation, and targeted therapy. The latter improved 
therapy in the last years, especially with identification of biomarkers, and the use of immune 
checkpoint- and kinase- inhibitors10.  
Lung cancer is classified via TNM staging, T for primary tumor extent, N for involvement of 
lymph nodes, and M for metastasis. Tumors will be detected via CT, while N and M staging is 
done via CT and PET-CT (positron emission tomography). T is subclassified in T0 – T4, 
3 Introduction 
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dependent on tumor size and invasiveness. Tis is defined as carcinoma in situ, is a non-invasive 
tumor in early development and can be fully resected. N1-N3 staging is done dependent on 
locality of cancer cells in lymph nodes. M staging is from M0-M1c and classifies the existence 
of metastasis and if they are regional or extra thoracic11.   
Treatment possibilities are dependent on the staging. Surgery will be done in early stages and 
tumor sizes < 4 cm. The 5-year survival rate is then between 75 – 80%. In patients with more 
advanced primary tumor surgery is followed by adjuvant chemotherapy or irradiation. If the 
tumor size limits the success of surgery a preoperative neoadjuvant chemotherapy (e.g., 
Cisplatin) can be a choice. When metastases are present in lymph nodes survival rates and 
treatment options are strongly dependent on localization and number of lymph node 
metastasis, but will be a combination of irradiation, chemotherapy, and surgery. Patients with 
multiple metastasis will be treated palliative. Positive results are also achieved with targeted 
therapy, with which survival can be prolonged for years in patients with advanced NSCLC12. 
This possibility is achieved by tremendous efforts to generate genetic profiles of the disease, 
like The Cancer Genome Atlas (TCGA) is doing7. Since now, common drug targets are ALK 
translocation (e.g., Alectinib), ROS1 translocation (e.g., Crizotinib), EGFR (e.g., Osimertinib 
for exon 19 deletion, L858R, T790M, and other mutations), and BRAF V600E mutations (e.g., 
Dabrafenib)13,14. Targeted therapy has the advantage of less side effects, oral application, and 
better life quality for the patient. Often secondary resistance appears in the first months of 
treatment and the drug needs to be changed, so is the T790M mutation the most common 
secondary resistance mutation in patients with an EGFR abnormality14. Besides tremendous 
efforts, the most commonly mutated oncogene in lung adenocarcinoma, KRAS is still a not 
druggable target15. In case of no detection of targets in the genetic profile of the lung tumor 
such as ROS-1, ALK, or EGFR and in higher progressed stages, patients can be given immune 
checkpoint inhibitors, such as against Programmed Cell Death-Ligand 1 (PD-L1). The 
treatment is based on manipulation of the tumor-host interaction. When T-cell are recruited in 
an area of inflammation or cancer growth, they secrete interferon-γ, which stimulates the 
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production of PD-L1 by tumor cells. The subsequent binding of the ligand to its receptor PD-1 
on the surface of T-cells leads to T-cell death, thereby stopping the immune response against 
the tumor. If PD-L1 is expressed in > 50% tumor cells, a monotherapy with PD-L1 inhibitor 
(e.g., Nivolumab, Pembrolizumab) can be started. By antagonizing the PD-1 receptor, the 
suppression of the immune attack can be prevented, and tumor cells can be recognized and 
cleared16.  
  The KRAS oncogene 
 The oncogenic RAS family  
The family of rat sarcoma (RAS) proto-oncogenes includes three members (HRAS, KRAS, and 
NRAS) encoding 4 proteins: HRAS, KRAS4A, KRAS4B, and NRAS, sharing 80 – 90% 
sequence identity15. The KRAS isoform is one of the most common mutated oncogenes in 
human cancers and related to poor prognosis17. All forms play a central role in various human 
cancers. They first were identified 1964 (KRAS) and 1967 (HRAS) in viruses being responsible 
for the malignant changes in bladder and lung carcinoma cells, later their human homologs 
were discovered and with this their importance in cancer biology. KRAS and HRAS were 
named after their ability to cause sarcomas in rat, adding their discovers names Kirsten and 
Harvey. First, they were understood as virus proteins, causing the transformation of a normal 
gene into an oncogene. Ten years later the human cellular counterparts were found for HRAS 
and KRAS. NRAS was discovered 1983 in the DNA of a neuroblastoma patient sample and 
named thereafter18.  
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Figure 3: HRAS NRAS, and KRAS share 90% homolog sequence and only differ in the HVR 
(hypervariable region). Within the G domain lies the binding motif for GTP/GDP binding (switch I/II). 
Location of most common point mutation are in the G domain and highlighted as stars. In the HVR is 
the CAAX motif important for posttranslational modification and transportation. CAAX- tetrapeptide 
motif, cysteine, aliphatic residue, and X for any amino acid. Figure from Ryan et al.19.  
 
The 21 kD small GTPase proteins, attached at the cell membrane, translate extracellular 
signals, such as EGFR activation, to intracellular signaling cascades and beyond. G-proteins 
use an on or off conformation regulated by nucleotide binding via Switch I and II domains (Fig. 
3), with the GTP-bound form as active signaling state15,17. Receptor tyrosine kinases (RTK) 
such as epidermal growth factor receptor (EGFR) bind extracellular signals and undergo 
intracellular autophosphorylation, thereby recruiting adapter protein complex GRB2 (growth 
factor receptor bound 2) and SOS (son of sevenless, GEF protein), in that way binding RAS 
proteins (Fig. 4)20. The GTP to GDP hydrolysis is catalyzed by GTPase-activating proteins 
(GAP) like neurofibromin-1 (NF1), while guanine nucleotide exchange factors (GEF) direct 
GTP dissociation and new binding of GTP will follow due to its high cellular concentration21. 
Before Kras4B and other RAS isoforms become active, they perform multiple posttranslational 
modification steps (Fig. 4). First, a farnesyl group (F) is added to the carboxy terminus (CAAX 
tetrapeptide motif, cysteine, aliphatic residue, and X any amino acid) by farnesyltransferase 
enzymes. As a second step, the AAX tetrapeptide termini of the prenylated RAS is cleaved by 
the protease RCE1 (Ras-converting enzyme 1), leaving only a cysteine residue. This will be 
carboxymethylated (M) by isoprenylcysteine carboxylmethyltransferase (ICMT) and finally 
KRAS4B is integrated into the cell membrane by adding lysine residues and being transported 
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by phosphodiesterase δ (PDEδ). The other RAS isoforms get palmitoylated at the SH group 
of the amino acid cysteine22. All proteins share same highly conserved catalytic G-domains of 
165 amino acids (aa), but differ in the 25 aa long hypervariable region (HVR), changing 
posttranslational modification, localization, and interaction with effector proteins23. In there lies 
KRAS4B’s higher oncogenic potential, therefore representing the most interesting drug 
target15. Regardless of their high degree of sequence homology, Ras proteins are not 
functionally comparable. For instance, knockout of the KRAS gene in mouse embryos is lethal, 
while deletion of either HRAS or NRAS is not15,24. Unique to KRAS4B is its ability to bind 
calmodulin and fully activate PI3K/AKT/mTOR signaling, making KRAS4B signaling more 
effective23. While NRAS and KRAS4A are farnesylated and palmitoylated, KRAS4B is only 
farnesylated and HRAS is double palmitoylated and farnesylated. Whereas farnesylation is a 
permanent PTM, palmitoylation can be reversed. This also implies different binding capabilities 
to chaperons, PDE transport proteins, and scaffolding proteins like galectin-125. Activating 
KRAS point-mutations, a single amino acid substitution, occur most frequent in codon 12 
(accounting for 90% of entire mutations in the KRAS gene) and 13, mainly G12C, G12D and 
G12V, while NRAS point mutations are predominantly in codon 61 (60%), and HRAS both in 
codon 12 and 61 (30%)17,21,23. The KRAS mutations are found in 25-30% smokers (mainly 
G12C) versus 5% in nonsmokers (mainly G12D)8. The KRAS mutation per se is more 
frequently mutated in smokers than non-smokers26,27. Hyperactive KRAS affects various 
hallmarks of cancer, cell proliferation, migration, metastasis, angiogenesis, inflammation, and 
apoptosis evasion and is exclusive among its family members since KRAS has a considerably 
higher mutation frequency in human cancer23. NRAS is mainly mutated in hematopoietic 
malignancies, HRAS in skin and head and neck cancer, while KRAS mutations appear in 
pancreatic (86 – 96%), colon (40 – 54%), and lung adenocarcinoma (27 – 39%)24,28.  
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Figure 4: Overview of the KRAS life. The KRAS protein needs posttranslational modification steps for 
full activation and integration in the plasma membrane. GTP binding leads to full KRAS activation and 
of multiple effector pathways like RAF/MAPK or PI3K/AKT/mTOR. This affects cell-autonomous and 
non-cell-autonomous processes. KRAS can be inhibited at multiple steps with different preclinical drugs 
(named in red) targeting different proteins (in grey, or KRASG12C, or downstream proteins such as RAF 
or MEK). -CAAX tetrapeptide motif, cysteine, aliphatic residue, and X for any amino acid; -F, farnesyl-
tail; -M, methylgroup;  RTK, receptor tyrosin kinase; GRB2, growth factor receptor bound 2; SOS, son 
of sevenless; GEF, guanine nucleotide exchange factor; GAP, GTPase-activating protein; PDEδ, 
phosphodiesterase δ; ICMT, isoprenylcysteine carboxylmethyltransferase; RCE1, Ras-converting 
enzyme 1; FTase, farnesytransferase.  
 
Why the isoforms are predominant expressed in different cancer types and why they arise from 
different germ layers are questions still unsolved (Fig. 5A, B). Experiments with F9 mouse 
embryonal carcinoma stem cells have shown that only hyperactive KRAS, but not HRAS or 
NRAS can sustain cell proliferation and stem cell characteristics, and thereby promote 
tumorigenesis of these endodermal progenitor cells, while mutant HRAS initiated cell 
differentiation. A possible explanation could be the differences in the HVR region, leading to 
different RAS localization and effector binding, and downstream signaling29. Another 
interesting experiment showed that the tissue-specific expression of isoforms is predominantly 
regulated via regulatory elements in the promotor regions. When expressing mutant HRAS 
under the control of the KRAS promotor, lung tumorigenesis was inducible in these genetic 
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modified mice24. Additional topic of interest is why specific point mutations are in context with 
disease progression. So is the KRASG12V mutation in NSCLC and colon cancer more harmful 
than KRASG12D, and only one dissimilar amino acid can make a difference in the transformation 
of the KRAS protein24. Also when testing different mutant forms of KRAS the codon 12 allele 
had the highest transformation capability when expressed in murine fibroblasts17.  
 
Figure 5: Differences in the RAS isoforms KRAS, NRAS, and HRAS. (A) Tissue expression of the three 
isoforms. (B) Three embryonic layers give rise to specific RAS isoforms. (C) KRAS is secreting CCL2, 
while NRAS is acting via CXCL5, resulting in different pathological profiles. Figure from Spella et al.30.  
 
 KRAS downstream signaling and beyond  
KRAS is an important, multitasking mediator of a huge signaling network and its dysregulation 
affects all hallmarks of cancer (cell proliferation, migration, apoptosis evasion, metastasis, 
angiogenesis, and inflammation). The two most well studied downstream effector pathways 
are mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/ 
serine/threonine kinase 1 (AKT)/ mammalian target of rapamycin (mTOR). Active KRAS 
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recruits rapidly accelerated fibrosarcoma (RAF) protein kinases to the plasma membrane 
including BRAF and CRAF, both potent oncogenes themselves. Dimerization activates 
mitogen-activated protein kinase kinase 1/2 (MAPKK/MEK 1/2) and extracellular-signal-
regulated kinase 1/2 (ERK 1/2) via phosphorylation20. This stimulates downstream factors 
including variant transcription factors for expression of cell cycle progression like cyclin D131,32. 
The MAPK pathway is thought to be the most important signaling cascade for the oncogene 
and KRAS mutations are mutually exclusive with other molecules of this pathway like EGFR 
and BRAF33. KRAS also interacts with PI3K, which phosphorylates PIP2 to PIP3 
(phosphatidylinositol-4,5-bisphosphate to -3,4,5-trisphosphate) and subsequently recruits AKT 
to the plasma membrane. AKT phosphorylates and activates multiple targets, such as pyruvate 
dehydrogenase kinase 1 (PDK1) and mTOR. The tumor suppressor phosphatase and tensin 
homolog (PTEN) can inactivate this cascade34. PI3K/AKT/mTOR signaling has numerous 
targets including nuclear factor-kappaB (NF-ĸB), pro-survival mediators, and regulators of 
protein translation and cell growth. The NF-ĸB pathway itself is tightly linked to inflammation 
and cancer progression, but in particular to KRAS mutant cancer types like lung and pancreatic 
cancers35,36. Since NF-ĸB activation is controlled via its activating IĸB kinases IKKα/β, and the 
degradation of the inhibitors of ĸB, called IĸBs or the non-canonical IĸB kinase TBK1, these 
regulators are seen as possible new targets37–39. One out of many effects of this signaling is 
the regulation of apoptosis suppression through upregulation of IAP’s (inhibitor of apoptosis 
protein) or pro-apoptotic B-cell lymphoma 2 (BCL-2) family members like Bcl-2-Antagonist of 
Cell Death (BAD)15,24. If the upstream activator EGFR is  absent, calcium-bound calmodulin 
(CaM/Ca2+) can close this gap and fully stimulate KRAS signaling, a mechanism often 
hyperactive in oncogenic signaling and unique to KRAS4B32. Different downstream pathways 
are tissue-specific, signaling via PI3K/AKT/PDK1 is crucial for PDAC development, while 
CRAF/MAPK is essential for NSCLC development. This makes it necessary to distinguish the 
tissue-specific efficacy of drugs targeting KRAS downstream effectors33,29.  
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KRAS is a potent oncogene acting cell-autonomous, but it also has huge control over non-cell-
autonomous mechanisms. This is presented by its ability to change the heterocellular tumor 
microenvironment by extracellular matrix (ECM) remodeling, metabolic reprogramming, 
inflammatory cell infiltration, endothelial cell recruitment, and fibroblast modulation15,31,40–43. 
The remodulation of the ECM by hyperactive KRAS was already published 1988, and is 
possible through upregulation of matrix metalloproteases (MMP) degrading type IV collagen40. 
Furthermore, oncogenic KRAS controls angiogenesis, the building of new blood vessels, by 
increasing vascular endothelial growth factor A (VEGFA) expression. In context to malignant 
pleural effusion (MPE), that KRASMUT tumor cells need paracrine C-C motif chemokine ligand 
2 (CCL2) signaling to surrounding myeloid cells such as mononuclear and mast cells (Fig. 5C). 
In turn, myeloid-derived interleukin-1β (IL-1β) can selectively trigger NF-κΒ activation in 
KRASMUT cancer cells via high expression levels of IL1R1 and inhibitor of NF-κΒ kinase alpha 
(ΙΚΚα), by this presenting a noticeable therapeutic target for KRASMUT lung cancer36,41. In 
addition KRAS driven PI3K/AKT signaling can promote vascularization through NF-ĸB 
mediated interleukin-8 (IL-8) expression44. These non-cell autonomous mechanisms are of 
high importance for survival and evasion of tumor cells and basis of aggressive KRAS mutant 
cancer types24. It presents a topic of huge interest in KRAS research: KRAS dependent 
regulation of the inflammatory response and recruitment of inflammatory mediators to the 
tumor microenvironment. Oncogenic KRAS is proven to recruit immune cells to the tumor 
environment via secretion of chemokines including IL-8, IL-1, IL-6, CXCL-1, CCL2 and CCL-5 
leading to control multiple favorable mechanism for cancer progression24,36,43.  
 Drug targets of oncogenic KRAS  
So far, efforts to drug the oncoprotein were unfruitful, although research is ongoing for over 30 
years. Compared to the successes of FDA approved small molecules for other oncogenes, the 
development for the most important cancer driver KRAS is lacking tremendously behind. The 
scientific community is pushing research forward (see the National Cancer Institute (NCI)- 
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supported RAS Initiative, https://www.cancer.gov/research/key-initiatives/ras) to develop 
KRAS inhibitors, a game changing finding with tremendous impact in cancer therapy and 
patient survival45. One of the first indirect attempts in the 1990s was inhibiting RAS 
farnesylation, a mandatory posttranslational lipid modification for full activation and 
localization, which were proven unsuccessful in phase III clinical trials (Lonafarnib, Tipifarnib) 
due to compensatory enzymes like geranylgeranyl transferases (GGT, Fig. 4)42. In the first 
years of RAS research, studies were conducted with HRAS models, assuming same functions 
for all RAS isoforms. This was the main pitfall for FTIs in clinical trials46. Another attempt was 
targeting the PTM step of methylation by inhibiting ICMT with the molecule cysmethynil 
resulting in mislocalization of KRAS and showing significant tumor growth reduction in severe 
combined immunodeficient (SCID) mice harboring PC-3 (prostate cancer-3) cell line derived 
flank tumors (treatment with 100 mg/Kg drug ip every 48 h)47,48. More recent studies focused 
on blocking the KRAS transport protein phosphodiesterase δ (PDEδ) and thereby interfering 
with the shuttling and plasma membrane integration of KRAS49. One such drug, deltarasin, is 
competing with KRAS for the binding pocket of PDEδ. In nude mice models with pancreatic 
xenografts daily ip injection of 15 mg/Kg deltarasin was successful in decreasing tumor growth. 
A similar inhibitor is salirasib, which removes the farnesylated and attached KRAS protein from 
the membrane by mimicking active KRAS50. The KRASG12C point mutation can be blocked with 
the compound AA12, harboring a thiol (SH) group51. With this the molecule binds via disulphide 
(S-S) bonds to the cysteine residue at the specific pocket of mutant KRAS, but the S-S bonds 
are degraded rapidly in the cells. Since direct allosteric inhibition of mutation specific sites 
would be the most specific option, multiple studies of drug structure optimization are 
ongoing52,53. The biotechnology company AMGEN has just presented their outcome of a 
clinical trial I study with the KRASG12C inhibitor AMG510 with promising results at multiple 
oncology meetings (https://clinicaltrials.gov/ct2/show/NCT03600883)54. Not feasible is 
targeting the GTP binding pocket for GDP/GTP. Picomolar concentrations of GTP are sufficient 
for KRAS activation, but micromolar concentrations of GTP are present in the cell20. 
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Alternatively, researchers search for synthetic lethality partners of mutant KRAS, since 
oncogene addiction makes cancer cells vulnerable and would be exclusive to the cancerogenic 
state of the cells. Examples for this approach are Serine/threonine Kinase 11 (STK11/LKB1), 
TANK Binding Kinase 1 (TBK1), and Cyclin Dependent Kinase 4 (CDK4), which drive cell 
survival selectively in KRAS-dependent cancer cells37,55,56. Scholl et al. identified STK11 
through high-throughput screenings using RNA interference against a huge library of targets. 
The protein is involved in cancer-specific mechanisms to evade apoptosis. In particular, STK11 
can suppress BAD, a proapoptotic protein of the BCL-2 family55. With the same method and 
RNA libraries of the Broad Institute RNAi Consortium (TRC) Barbie et al. found TBK1 as 
promising synthetic lethality partner of KRAS. By inhibiting TKB1 and subsequent NF-ĸB 
signaling pro-survival responses were suppressed37.  
In addition to studies focusing on processing and structural features of KRAS itself, 
downstream proteins of RAS signaling, RAF, MEK or PI3K, are studied intensively. Many 
inhibitors are in clinical test phases, some already food and drug administration (FDA) 
approved and in use for other diseases. They are still predominantly not clinically relevant for 
RAS mutated cancers due to countervailing pathways and feedback loops46,57. Vemurafenib is 
in use for Raf mutant tumors such as melanoma (Fig. 4). Unfortunately, RAF inhibitors 
upregulate MAPK signaling when KRAS is mutant by activating a positive feedback loop. A 
more promising option are various MEK inhibitors like Trametinib31. However, KRAS can affect 
multiple pathways and therefore drugging only one target might be useless. MEK inhibitors 
tested could not show clinically relevant effects in NSCLC patients, evaluated as monotherapy 
or in combination with chemotherapeutics like Pemetrexed or Docetaxel58. Combination 
therapies to attack hyperactive KRAS could be therapeutically more interesting, but this option 
is proven to be significantly toxic for the patients59. A dual treatment with MEK and PI3K 
inhibitors showed efficacy in mice models, but in clinical trials tolerable doses were not 
successful and dose increase would be too toxic for the patients19.  
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Why is the search for KRAS inhibitors still unfruitful? One fundamental error could be the use 
of conventional in vitro and cell-based assays for drug screenings, which cannot reproduce the 
very complex nature of a target like KRAS. Just recently Janes et al. reported different KRAS 
dependencies in vitro versus in vivo53. Chen et al. showed how different pancreatic cell lines 
behave after shRNA induced KRAS downregulation60. They and others describe the differential 
sensitivity to KRAS inhibition in in vivo systems compared to cellular models. In comparison to 
that, mouse models of mutant KRAS are a highly reliable source in cancer studies57,61. Findings 
like that get more and more accepted as KRAS-specific un-druggability in vitro. The role of the 
oncogene beyond the cancer cell itself is huge with the inflammatory response playing an 
important role for tumor development and cancer treatment.  
 Immune system in Cancer progression and treatment  
The immune system (IS) has tremendous impact on cancer development and progression and 
was therefore integrated in the original 6 hallmarks of cancer postulated 2000 by Weinberg 
and Hanahan. They enlarged their proposal 2011 to 10 hallmarks of cancer including tumor-
promoting inflammation as one big new point to consider (Fig. 6)62,63. Rudolf Virchow was one 
of the first linking inflammation and abnormal cell proliferation even before a microscope was 
invented64. The immune system has a dual role in cancer progression since it recognizes and 
destroys cancer cells, but by this it can select the fittest cancer cells to survive. The immune 
cells surrounding the tumor create an environment which can as well be positive for tumor 
outgrowth65. Host-derived cytokines can defeat tumor development, but cancer cells can also 
exploit these cytokines to promote tumor growth, angiogenesis, and increase resistance to 
apoptosis66.  
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Figure 6: The former 6 hallmarks of cancer from 2000 and the new version from 2011. The authors re-
evaluated and supplemented them with the new hallmarks avoiding immune destruction, tumor-
promoting inflammation, genome instability & mutation, and deregulating cellular energetics. For each 
capability are inhibtors in clinical development or in clinical use. Figure from Hanahan et al.63.  
 
The IS is the defense system against any toxic, harmful particle, and within this system, the 
innate IS represents widely first-line defense mechanisms, while the adaptive IS produces 
specific antigens for pathogens66. Both have their own task force, a panel of cell types 
specialized for either acute or long-term defense. The cells of origin are leukocytes (white blood 
cells) from hematopoietic stem cells found in bone marrow, placenta, and peripheral blood67. 
Leukocytes can amount up to 50% of full tumor mass68. These cells differentiate into myeloid 
or lymphoid progenitors. The latter divides in B-, T-, and NK cells, which belong in most parts 
to the adaptive IS. Myeloid progenitors divide further in granulocytes (monocytes, 
macrophages, mast cells, neutrophils, basophils, and eosinophils), platelets, and 
erythrocytes67. The adaptive IS acts slow, but produces specific antibodies and remembers its 
response for future action via antigen-specific receptors on the surface of T- and B- cells to 
foster targeted effector responses69.  
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Figure 7:  Adaptive and innate immune system and their main cells of action. For rapid defense the 
innate immune response with its cellular components is in charge, granulocytes (basophils, eosinophils, 
and neutrophils), natural killer cells, macrophages, dendritic cells and mast cells. The slower defense is 
the adaptive immunity, but it has increased antigenic specificity and memory. It involves antibodies, B 
cells, CD4+ and CD8+ T lymphocytes. At the interface of both immune responses are natural killer T cells 
and γδ T cells, cytotoxic lymphocytes. Figure from Dranoff et al. 66.  
 
The innate IS recognizes a large group of harmful microorganisms expressing pathogen-
associated molecular patterns (PAMP) like bacterial lipopolysaccharide, peptidoglycan, 
bacterial DNA, double-stranded RNA) via their pattern-recognition receptors (PRR). In case of 
recognition the immune cell immediately reacts without further proliferation. By the recognition 
of PAMPs inflammatory cells such as macrophages and mast cells get activated and produce 
and release cytokines (tumor necrosis factor TNFα, IL-1β, IL-6) and proinflammatory 
chemokines (IL-8, CCL2), which stimulate recruitment of more immune cells to the site of 
inflammation68. One subset of PRR are the toll-like receptors (TLR), which activate multiple 
downstream signaling cascades after PAMP binding. Among those the NF-ĸB activation leads 
to transcription of many inflammatory mediators as mentioned above70. The innate IS and its 
role in chronic inflammation is a well-studied subject and tightly linked to cancer. “Wounds that 
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never heal” are thereby a huge risk factor for cancer development causing approximately 25% 
of all cancers68,71. They share common pathways, such as constant tissue damage and their 
need to proliferate, increased cell survival, migration, and enhanced angiogenesis68. Extrinsic 
factors can cause constant irritation which can lead to tumor development, such as tobacco 
smoking as main reason for NSCLC, helicobacter pylori infection triggering chronic gastritis, in 
turn causing 75% of stomach cancers, pancreatitis as main risk factor for pancreatic cancer, 
and Crohn’s disease causing a tenfold higher colon cancer risk26,68,72. The general mechanism 
connecting inflammation and cancer is that both extrinsic factors (inflammation) and intrinsic 
pathways (genetic events such as MYC, RAS, RET mutation) promote activation of 
transcription factors (fe NF-ĸB, STAT3), transcribing cytokines (IL-6, IL-22, IL-1, CCL2, and 
more), which attract immune cell populations and in turn infiltrating tumor tissue. They again 
activate transcription of pro-tumorigenic cytokines ending in a positive feedback loop for tumor 
progression73. In KRAS mutant cancer it was shown that by expressing high amounts of 
cytokines like CCL2, myeloid cells get recruited to the tumor environment thereby promoting 
further tumor growth as well as malignant pleural effusion41. The strong involved NF-kB 
pathway supports this interplay of KRAS mutant cancer cells and inflammatory response36.  
 Outlook 
Here we show that KRAS inhibition through genetic manipulation or 3 inhibitors (deltarasin, 
AA12, cysmethynil) show primary resistance in vitro in lung cancer cell lines, proven with 
different assays. However, they do have mutation specific effects in vivo in immunocompetent 
flank mouse models of lung cancer. This led us to assume that non-cell autonomous effects of 
KRAS are of much higher importance than KRAS-controlled cell intrinsic signaling. By 
analyzing the gene expression profile of a panel of murine cell lines we teased out a Kras-
mutant specific gene-set which was highly similar to a human KRAS-signature, as well as 
inflammatory response signaling. Consistent with similar expression profiles and their 
validation used to study mast cell recruitment and Kras-induced MPE formation done by 
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Giannou et al., Marazioti et al., and Agalioti et al. we found the inflammatory mediators Il1r1 
and Ccl2 highly upregulated36,41,43. The authors were able to show a KRAS-regulated 
expression of CCL2 which resulted in CCR+ myeloid cell recruitment to the tumor 
microenvironment. By this, host cell secreted IL-1β supported MPE formation and tumor 
growth. In this piece of work, we further analyzed the role of both inflammatory mediators in 
response to KRAS inhibition. We show that the KRAS-specific drug deltarasin inhibits the IL-
1R1 expression of KRAS-mutant tumor cells and so stopping the cascade initiated by 
recruitment of myeloid cells to the tumor environment. Consequently, CCL2/IL-1β signaling is 
significantly lesser and KRAS-mutant tumor cells are not fueled anymore with this growth-
promoting mechanism. We propose that the KRAS/CCL2/IL-1β axis is not just responsible for 
MPE formation, but also plays a crucial role in effective inhibition of KRAS-mutant lung 
adenocarcinoma. For this reason, study design for KRAS drug development needs a shift 
towards in vivo screenings.  
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 Aim of this dissertation 
Background:  
 
 KRAS is one of the most mutated oncogenes in various cancer types and predicts 
decreased patient survival. 
 KRAS drug development is on-going, but so far failed in preclinical or clinical stages. 
 The immune system influences cancer progression and development. 
 KRAS mutant cancers are strongly dependent on their tumour microenvironment and 
inflammatory signalling offering new possibilities for treatment. 
 
Study highlights contributed by this work are:  
 Evaluation of different preclinical KRAS inhibitors in vitro with multiple assays and a 
large panel of human and murine cell lines.  
 Proof of a huge discrepancy between in vitro and in vivo findings related to KRAS 
inhibition.  
 Identification and validation of a mechanism for the in vivo-restricted efficacy of KRAS 
inhibitor deltarasin.  
 Determination of the requirement for the KRAS/CCL2/IL-1β axis to successfully inhibit 
KRAS. 
 Proof-of-concept human data supporting the existence of the proposed mechanism in 
human cancer.  
 KRAS drug development can be improved by an in vivo setting.  
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4. Materials  
 Antibodies  
Table 1. Antibodies 
Methoda Target protein Providers Catalog 
number 
Dilution 
WB p-ERK Santa Cruz 
Biotechnology 
sc-7383 1:1000 
WB t-ERK Santa Cruz 
Biotechnology 
sc-514302 1:1000 
WB GAPDH Cell Signaling #2118 1:2000 
WB rat anti-mouse 
IgG 
Abcam ab131368 1:10000 
WB anti-rabbit IgG 
VHH 
Abcam ab191866 1:10000 
IF IL-1β-Alexa488 Santa Cruz 
Biotechnology 
sc-515598 
AF488 
1:50 
IF CCR2 Thermo Fisher 
Scientific 
PA5-23043 1:50 
IF DAPI Staining 
Solution 
Abcam ab228549 300 nM 
IF donkey anti-
rabbit IgG 
AlexaFluor647 
Abcam ab150075 1:500 
IF normal mouse 
IgG2a Alexa 
Fluor488 
Santa Cruz 
Biotechnology 
sc-3891 1:50 
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 Assays & Kits 
BCA assay PierceTM Rapid gold BCA protein assay; Thermo Fisher 
Scientific; Waltham, USA  
cDNA synthesis iScript Advanced cDNA synthesis kit for RT-qPCR; Bio-rad 
Laboratories; Hercules, USA 
DNA purification NucleoSpin® Gel and PCR Clean-up; Macherey-Nagel; Düren, 
Germany 
ELISA  human MCP-1(CCL2); murine JE/MCP-1 (CCL2); ABTS ELISA 
buffer kit; Peprotech; London, UK  
Mycoplasma Detection MycoAlert; LONZA; Verviers, Belgium 
Plasmid purification NucleoSpin® Plasmid easyPure; Macherey-Nagel; Düren, 
Germany 
qPCR Lightcycler 480 Sybr Green I Master; Roche Diagnostics; 
Mannheim, Germany 
RNA isolation Trizol LS reagent; Thermo Fisher Scientific; Waltham, USA 
RNA purification RNAeasy mini kit; Qiagen; Hilden, Germany 
Cell viability assay  WST-8/ CCK-8 (cell counting kit 8) assay; Bimake; Munich, 
Germany 
 Buffers 
PBS    NaCl   8 g 
Na2HPO4  1.15 g  
KH2PO4  0.2 g 
H2O   to 1 L 
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10x SDS Running buffer Tris-base  30 g 
   Glycerin  144 g 
   SDS   10 g  
   H2O   to 1 L 
 
10x Transfer buffer pH 8.3 Tris   30 g 
   Glycine  144 g 
   SDS   5 g     
    H2O   to 1 L 
 
1x Transfer buffer (TB) 10x TB  100 ml 
    Methanol  100 ml 
    H2O   to 1 L 
 
Citrate buffer pH 6.0  Citric acid  2.1 g 
   H2O   to 1 L 
 
50x TAE buffer  Tris    242 g  
0.5 M EDTA pH 8.0  100 ml  
Acetic acid   57.1 ml  
H2O    to 1 L  
 
6x Protein loading dye 1 M Tris HCL  3 ml 
   Glycerol  1.5 ml 
   SDS   0.6 g 
   Bromophenol blue 1 mg 
   H2O   to 20 ml 
 
GdmCl buffer 6 M  10 M GdmCl stock 12 ml (6 M final) 
    0.5 M TCEP stock 0.4 ml (10 mM final) 
    0.5 M CAA stock 1.6 ml (40 mM final) 
    1.5 M Tris pH 8.5 1.3 ml (100 mM final) 
   H2O   to 20 ml 
 
 Cell lines 
Table 2. Cell lines 
Organism 
Cell line Tissue origin KRAS mutation status 
C57BL/6 mouse LLC Lewis lung  
carcinoma 
G12C 
C57BL/6 mouse MC38 Colon  
adenocarcinoma 
G13R 
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C57BL/6 mouse AE17 Malignant  
pleural mesothelioma  
G12C 
C57BL/6 mouse B16F10 Malignant  
skin melanoma 
none 
C57BL/6 mouse PANO2 Pancreatic 
adenocarcinoma 
none 
C57BL/6 mouse CULA Urethane-induced  
lung 
adenocarcinoma 
none 
FVB mouse FULA Urethane-induced  
lung 
adenocarcinoma 
Q61R 
Human A549 Lung  
adenocarcinoma 
G12S 
Human H460 Lung large  
cell carcinoma 
Q61H 
Human H358 NSCLC G12C 
Human H358M Bronchiolo-alveolar 
carcinoma 
G12D 
Human H1944 NSCLC G13D 
Human HOP-62 Lung  
adenocarcinoma 
G12C 
Human H520 Squamous  
cell carcinoma 
none 
Human EKVX Lung  
adenocarcinoma 
none 
Human H1299 NSCLC none 
Human H3122 NSCLC none 
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 Drugs 
AA12   CAS 1469337-95-8; Selleckchem #S7331; Houston, TX, USA 
Cysmethynil  CAS 851636-83-4; Cayman Chemicals #14745; Ann Arbor, MI, USA 
Deltarasin CAS 1440898-82-7; Tocris Bio-Techne #5424; Wiesbaden-
Nordenstadt, Germany 
BV6 CAS 1001600-56-1; BioVision Incorporated # B1332-5; Milpitas, CA, 
USA 
Z-DEVD-FMK CAS 210344-95-9; Cayman Chemicals #T6005; Ann Arbor, MI, USA 
 E. coli bacterial strains  
DH5α Genotype: F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rK-, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
Source:  #18265017; Thermo Fisher Scientific; Waltham, USA 
 Lab equipment 
ABI2000 Bioanalyzer Agilent, Santa Clara, CA 
Autoclave Varioklav, H+P Labortechnik, Oberschleissheim, Germany 
Balances  PM 4800 Delta Range, Mettler-Toledo, Columbus, OH, USA 
2001 MP2, Sartorius, Göttingen, Germany 
Bioruptor  Bioruptor Plus sonication device, Liège, Belgium 
Centrifuges    Mikro 200R, Hettich, Tuttlingen, Germany 
Rotanta 460R, Hettich, Tuttlingen, Germany 
Decloaking chamber Medical decloaking chamber, Biocare Medical, Pacheco, USA 
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Electrophoresis Mini Protean-Tetra Cell System, Bio-Rad Laboratories Inc., 
Hercules, CA, USA  
Gel imaging system Chemidoc XRS+ System, Bio-Rad Laboratories Inc., Hercules, 
CA, USA 
Incubation shaker  HT Multitron, Infors, Bottmingen, Switzerland 
Incubator  BBD6220, Heraeus, Thermo Scientific, Waltham, MA, USA 
Ice machine    Ziegra, Isernhagen, Germany 
Laminar flow    LaminAir HB 2472S, Heraeus, Hanau, Germany 
Lightcycler 480 II   Roche Diagnostics, Basel, Switzerland 
Magnetic stirrer   MR3003, Heidolph, Kelheim, Germany 
KMO2 basic, IKA, Staufen, Germany 
Microplate reader  TECAN Sunrise microplate reader; Männedorf, Switzerland 
Microscope, inverted  Axiovert 40 C; Zeiss; Jena, Germany 
Microscope, light  AxioImager.M2; Zeiss; Jena, Germany 
Microtome   Hyrax M55 cool-cut; Zeiss; Jena, Germany  
pH-meter    Inolab pH Level 1, WTW, Weilheim, Germany 
PCR cycler  Mastercycler gradient, Eppendorf AG, Hamburg, Germany 
Shaker   Duomax 1030, Heidolph, Schwabach, Germany   
Spectrophotometer   ND-1000, peqlab, Erlangen, Germany 
Thermoblock    Thermomixer 5436, Eppendorf AG, Hamburg, Germany 
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Water bath incubator  MA6, Lauda, Lauda-Königshofen, Germany 
Water preparation   Milli Q Advantage, Millipore, Billerica, MA, USA 
Western Blotting Mini Trans-Blot Cell System, Bio-Rad Laboratories Inc., 
Hercules, CA, USA  
 Plasmids 
The shRNA plasmids are pools of 3-5 lentiviral vector plasmids, which are coding for 19-25 
nucleotide (nt) long shRNA. They, the KrasG12C plasmid, and appropriate control plasmids can 
be transfected with common protocols and selected with puromycin for stable expression. 
Table 3. Plasmids 
Plasmid Insert Provider Catalog 
number  
GFP-KrasG12C_2B_puro* 
(pKrasG12C) 
mouse Kras 2B 
(G12C mutant) 
Addgene  64372 
Bicistronic_GFP_ires_puro* 
(pC) 
GFP fluorescent 
protein 
Addgene 64336 
murine shKras Pool of 3 shRNA 
constructs 
against mKras 
Santa Cruz 
Biotechnology 
sc-43876-V 
murine shCcl2 Pool of 3 shRNA 
constructs 
against mCcl2 
Santa Cruz 
Biotechnology 
sc-43914-SH 
random negative control 
shRNA (shC) 
Scrambled 
shRNA 
Santa Cruz 
Biotechnology 
sc-108080-V 
*Vector maps can be found in the Appendix and online at addgene.org 
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 Primers 
Oligonucleotides for qPCR were synthesized by Eurofins Genomics (Ebersberg, Germany).  
Table 4. Primers 
Primer Sequence Amplicon (bp) 
Murine Il1rF GCTGACTTGAGGCAGTT 200 
Murine Il1rR CATACGTCAATCTCCAGCGAC 
Human IL1R1F AGGTAGACGCACCCTCTGAA 154 
Human IL1R1R GCATTTATCAGCCTCCAGAGAAG 
Murine GapdhF CCCTTAAGAGGGATGCTGCC 124 
Murine GapdhR TACGGCCAAATCCGTTCACA 
Human GAPDHF TTAGGAAAGCCTGCCGGTGA 157 
Human GAPDHR GGCGCCCAATACGACCAAA 
F forward, R reverse 
 Mice strains  
The table below shows mice strains used for this study. The genetically engineered mice strain 
names are given by the mixed backgrounds (B6, C57BL/6; 129, 129 strain including subtype), 
followed by target gene and superscripted abbreviation “tm” for targeted mutation, allele 
number, creator’s lab code, and lab code of provider (“J”, Jackson laboratory).  
 
Table 5. Mice strains  
Strain Background Provider Catalog 
number  
FVB/NJ  FVB Jackson Laboratory (Bar 
Harbor, ME) 
001800 
C57BL/6J  C57BL/6 Jackson Laboratory  000664 
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B6(Cg)-Rag2tm1.1Cgn/J Rag2 Jackson Laboratory  008449 
B6.129P2-Cxcr1tm1Dgen/J C57BL/6 Jackson Laboratory  005820 
B6.129S2(C)-
Cxcr2tm1Mwm/J 
C57BL/6 Jackson Laboratory 006848 
B6.129S4-Ccr2tm1Ifc/J C57BL/6 or 
FVB 
Jackson Laboratory 004999 
Il1btm1Yiw mice C57BL/6 or 
FVB 
Dr. Yoichiro Iwakura 
(Tokyo University of 
Sciences, Japan) 
2157396 
(MGI) 
 Reagents 
Agarose Thermo Fisher Scientific, Waltham, USA 
BSA Santa Cruz Biotechnology, Dallas, USA  
Crystal Violet   Sigma-Aldrich, St. Louis, USA 
DMSO    Sigma-Aldrich, St. Louis, USA 
DNA Loading dye, 6x  Thermo Fisher Scientific, Waltham, USA  
DNA ladder, 1 kb  Thermo Fisher Scientific, Waltham, USA   
FBS    Thermo Fisher Scientific, Waltham, USA  
GeneJuice Transfection Merck KGaA, Darmstadt, Germany 
Reagent    
LB- Agar   AppliChem GmbH, Darmstadt, Germany 
LB- Medium   AppliChem GmbH, Darmstadt, Germany 
Midori green DNA Stain Nippon Genetics Europe GmbH, Düren, Germany 
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Mounting medium Fluorescence mounting medium, DAKO North America Inc., 
Carpinteria, USA 
Paraformaldehyde  Sigma-Aldrich, St. Louis, USA 
Trizol x 100   Thermo Fisher Scientific, Waltham, USA 
Trypsin   Thermo Fisher Scientific, Waltham, USA  
Pen/Strp   Thermo Fisher Scientific, Waltham, USA  
Phosphatase/- Protease-  Thermo Fisher Scientific, Waltham, USA 
Inhibitor Cocktail   
Protein loading dye   SERVA Electrophoresis GmbH, Heidelberg, Germany 
Protein marker  SERVA Electrophoresis GmbH, Heidelberg, Germany 
Puromycin   Abcam, Cambridge, UK 
RIPA    Thermo Fisher Scientific, Waltham, USA  
Xfect    Takarabio Inc, Kusatsu, Japan 
 
 Software 
Table 6: Software  
Software Use Link and Reference Provider 
Transcripto
me 
Analysis 
Console 
Software 
(TAC) 
Analysis of 
transcriptional 
expression 
differences of 
microarray data   
https://www.thermofisher.com/de/de/home/lif
e-science/microarray-analysis/microarray-
analysis-instruments-software-
services/microarray-analysis-
software/affymetrix-transcriptome-analysis-
console-software.html 
Thermo 
Fisher 
Scientific, 
Waltham, 
USA 
Broad 
Institute 
pre-ranked 
Computational 
method to find 
differences 
http://software.broadinstitute.org/gsea/index.j
sp74 
Broad 
Institute, 
Massachus
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Gene Set 
Enrichment 
Analysis 
(GSEA)  
within a gene 
set fe. between 
KrasMUT and 
KrasWT 
phenotypes or 
identification of 
signaling 
pathway 
members 
 etts 
Institute of 
Technology 
(MIT), CA, 
USA 
Wikipathwa
y analysis 
database of 
biological 
pathways 
https://www.wikipathways.org/index.php/Wiki
Pathways75 
National 
Institute for 
General 
Medical 
Sciences, 
Bethesda, 
MD, USA 
QuantaSoft Analysis of 
qPCR runs  
http://www.bio-rad.com/en-gr/sku/1864011-
quantasoft-software-regulatory-
edition?ID=1864011 
Bio-Rad 
Laboratorie
s Inc., 
Hercules, 
CA, USA 
ImageJ Immunoblotting 
processing and 
lane intensity 
quantification  
http://www.bio-rad.com/en-us/sku/1709690-
image-lab-software 
Bio-Rad 
Laboratorie
s Inc., 
Hercules, 
CA, USA 
G*Power Statistical 
program to 
calculate 
number of mice 
http://www.gpower.hhu.de/76 Heinrich-
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5. Methods  
 Chemicals and solutions   
AA12, BV6, cysmethynil, deltarasin, and Z-DEVD-FMK were dissolved in DMSO to a stock 
concentration of 10 mM, and stored at −80 °C. Further dilutions for in vitro assays were done 
in the right media. For in vivo injections deltarasin was dissolved to a final concentration of 15 
mg/kg in 100 µl PBS.  
Chemicals were obtained from different companies, among others Bio-Rad Laboratories 
(Hercules, CA, USA), Merck (Darmstadt, Germany), Biozym (Hessisch Oldendorf, Germany), 
Life Technologies (Carlsbad, CA, USA), GE Healthcare (Little Chalfont, Buckinghamshire, 
UK), Qiagen (Hilden, Deutschland), Roth (Karlsruhe, Germany), and Sigma-Aldrich (St Louis, 
MO, USA). Consumables were ordered from Corning (Corning, NY, USA), Eppendorf 
(Hamburg, Germany), Biozym (Hessisch Oldendorf, Germany), BD Biosciences, Nunc/Thermo 
Fisher Scientific (Waltham, MA, USA), and others.  
 Cell culture 
All murine and human cancer cell lines were chosen according to their Kras/KRAS mutation 
presence (table 2, supplementary figure S1). NCI-H460, -H358, -H358M, -H1944, -H1299, -
H3122, -H460, -H520, -HOP-62 (omitting NCI- from now on), EKVX, A549, LLC, B16F10, and 
PANO2 were ordered from the National Cancer Institute (Frederick, MD); MC38 cells were 
received as a gift from Dr. Timothy S. Blackwell (Vanderbilt University, Nashville, TN) and 
AE17 cells from Dr. YC Gary Lee (University of Western Australia, Perth, Australia)36,41,79,80. 
FULA1 and CULA cell lines were generated from C57BL/6 or FVB mice harboring primary lung 
adenocarcinoma developed after urethane exposure26. Benign samples including tracheal 
epithelial cells (TEC; cultured out from murine tracheas), whole murine lungs, bone marrow-
derived macrophages (BMDM; isolated from murine bone marrow and differentiated in vitro in 
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DMEM with 10% FBS and 20 ng/mL M-CSF), and mast cells (BMMC; murine bone marrow 
isolation followed by culturing in DMEM containing 10% FBS and monthly incubation with 100 
ng/mL IL-3 plus KITL) were prepared as described elsewhere26,36,43. Human cell lines were 
cultured in RPMI-1640, murine cell lines in DMEM supplemented with 10% FBS and 100 IU/ml 
penicillin/streptomycin. They were kept in a humidified incubator at 37 °C with 5% CO2. All cell 
lines included in this study were negative for mycoplasma Mycoplasma Spp and regularly 
checked via MycoAlert Mycoplasma Detection Kit.  
For passaging and splitting, confluent cells were washed once with 1x PBS and trypsinized for 
2-5 min. For sub-culturing, a splitting ratio of 1:2 to 1:10 was applied, or cells were seeded in 
dishes or multiwell-plates for experiments. Counting of cells was performed using a 
hemocytometer (Neubauer improved), after 10 min centrifugation (400 rpm) of trypsinized cells 
in full growth media following dilution of the cell pellet in fresh growth media. Following formula 
for calculating total cell number/ ml was used:  ⁄ =     ×
10.000 . For final dilution calculation the equation ×  = ×  was used.  
For freezing and thawing, cells were collected and centrifuged as described, and cell number 
was determined using the hemocytometer. Cell pellets were resuspended in freezing media 
containing FBS and 10% DMSO for cryoprotection. Vials were frozen at -80 °C overnight and 
moved to liquid nitrogen. Thawing was performed by letting cryovials carefully defrost in the 
37 °C water bath and then plated in fresh prewarmed full growth media.  
 Constructs 
Knockdown gene expression experiments were done using shRNA against Kras or Ccl2. 
Protein overexpression was performed using custom-made plasmids encoding mutant 
KrasG12C oncogene. Kras silencing was induced in LLC, AE17 and MC38, Ccl2 silencing in 
FULA1, and KrasG12C overexpressing in B16F10, PANO2, EKVX, and H3122. LLC, AE17 and 
MC38 shKras were produced as described elsewhere41. A similar strategy was applied for 
FULA1 shCcl2. For stable shRNA transfection, 105 tumor cells in 6-well culture vessels were 
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transfected with 5 μg DNA using Xfect reagent (Takara) and clones were selected by 
puromycin (2-10 μg/mL). After primary harsh selection, clones were picked, most efficient ones 
identified via ELISA assay and pooled. Puromycin treatment was reduced to 1 µg/ml for further 
cultivation to guarantee stable transfection with shCcl2. For negative and positive controls 
lentiviral plasmids expressing random scrambled shRNA were used. H3122 and EKVX cells 
were stably transfected with pKrasG12C or its homologous GFP backbone plasmid without 
KrasG12C. For this, 60% confluent cells were starved for 4 hours before transfection with 
GeneJuice reagent in a ratio of transfection reagent to DNA of 3 µl reagent to 1 µg DNA. After 
48 hours, media was replaced by media containing 0.5-15 μg/mL puromycin. Stable clones 
were selected and subcultured under constant antibiotic pressure. Validation was done with 
an inverted fluorescence microscope (Axiovert 40 C; Zeiss) and GFP expression. All plasmids 
for overexpression were made inhouse, deposited, confirmed, and repurchased from Addgene 
(Watertown, MA, supplementary figure S2 for plasmid maps). After receiving the plasmids as 
transformed bacteria in stab culture, bacteria were streaked out on a LB agar plate and 
incubated at 37°C overnight. A single colony was picked and inoculated overnight in LB media 
at 37°C. Plasmids were purified using the NucleoSpin® Plasmid easyPure kit, test digested 
with appropriate restriction enzymes according to company instructions (Promega GmbH, 
Mannheim) and controlled on an agarose gel (1% agarose in PBS-T (0,05%); 1 h, 100 V).  
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 In vitro cell culture assays  
 Cell viability assay 
In vitro cell proliferation of various cell lines (see 4.3) was determined using WST-8 assay 
(tetrazolium-1[2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium, 
WST-8 monosodium salt, Bimake) assay. The assays mechanism is hereby based on the 
activity of mitochondrial succinate dehydrogenases exclusively active in living cells. By adding 
the tetrazolium salt to cells and in presence of 1-Methoxy PMS, an electron carrier, reduction 
by these enzymes will take place and an orange, water-soluble formazan dye develops, directly 
proportional to the number of living cells and detectable at a specific wavelength (while cellular 
cofactors NADH/NADPH are oxidized). The water solubility of the dye is one of multiple 
improvements to former used MTT reagents81. 3000 cells/ well were plated in triplicates in 96-
well plates in media containing 5% FBS and allowed to adhere overnight. Cells were treated 
with different concentrations of drugs the next day (between 0 – 100 µM). 72 hours later 1:10 
solution and measured after 1- 4 hours incubation time on a TECAN Sunrise microplate reader 
at 450 nm. The plates were incubated at 37 °C in a 5% CO2 humidified incubator. For controls 
the maximal dosage of DMSO was used, in correlation to the highest drug concentration (2% 
of full sample volume), labeling DMSO control samples as controls (CTRL) subsequently. For 
drug combinations, different concentrations of deltarasin were combined with IC25 
concentrations of either BV6 or Z-DEVD-FMK or DMSO controls and incubated for 72 hours 
before measurement.  
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Figure 8: Mechanism of WST-8 assay. The tetrazolium salt is reduced to an orange formazan salt via 
intact cellular enzymes. This colour development is direct proportional to the viable cells and measurable 
at 450 nm. NAD/NADH, Nicotinamide adenine dinucleotide; NADP/NADPH, nicotinamide adenine 
dinucleotide phosphate; PMS, 5-methylphenazinium methyl sulfate; WST, tetrazolium-1[2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-teterazolium. Description of cell counting kit-8, 
online available at: https://www.bimake.com/product/vita-orange-cell-viability-reagent.html (accessed 
13 May 2019). 
  
 Colony formation assay 
For detection of colony formation, 300 cells were plated in triplicates in 6-well plates in 5% 
FBS-containing media. 24 hours later murine cell lines were treated with 1 µM deltarasin, 
human cell lines with 2 µM deltarasin. Media was replaced with drug-free media 72 hours later. 
Incubation kept going until ≤ 50 colonies were formed. Cell colonies were fixed with 80% 
ethanol, stained with 0.5% crystal-violet diluted in distilled H20, and counted. Pictures were 
taken with an AxioImager.M2. Colonies were counted in each well and all cellular experiments 
were independently repeated at least three times80.  
 Immunological methods 
 Western blot analysis  
Protein lysates were prepared as following: Adherent cells were cultivated in FBS-free medium 
4 hours prior to cell lysis, then washed with PBS and scraped off for collection in Eppendorf 
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tubes. After centrifugation to remove debris (1000 rpm, 10 min), cell pellets were lysed using 
RIPA buffer containing phosphatase/protease inhibitor cocktail. Lysis took place for 30 min on 
ice. To determine protein concentration a bicinchoninic acid assay (BCA) was done according 
to manufactures protocol and a standard curve was produced to calculate protein amount in 
experimental samples. The BCA assay uses the reduction of Cu2+ to Cu1+ by proteins in an 
alkaline medium which result in a colored reaction with an absorbance at 480 nm. Protein 
lysates were diluted in 1x SDS sample buffer to a final concentration of 1 µg/µl and heated up 
at 95 °C for 5 min before storage at -20 °C. Protein samples were separated by mass using 
SDS- PAGE (80 V, 20 min followed by 100 V, 40 min) and transferred to nitrocellulose 
membranes following standard protocols, using the 10x transfer buffer, 10% methanol and VE-
H2O. Briefly, electrophoretic transfer of proteins was achieved using wet transfer techniques 
and nitrocellulose membrane (100 V, 60 min). After blocking in 5% BSA solution in PBS-T for 
1 h, immunostaining was performed over night with antibody dilutions in PBS-T and 1% BSA 
at 4°C shaking (see 4.1, table 1. antibodies). Anti-t-ERK, anti-p-ERK, and anti-GAPDH 
antibodies were obtained from Santa Cruz Biotechnology. Secondary antibodies were applied 
next day in a 1:10000 dilution in PBS-T for 1 h after 3x washing for 10 min with PBS-T.  
 Immunofluorescence 
Murine tumor tissue samples were fixed in paraformaldehyde overnight, embedded in paraffin, 
and shipped from Patras, Greece, to Munich, Germany. Paraffin blocks were cut into 3 µM 
sections with a Hyrax M55 cool-cut microtome (Zeiss). After overnight incubation at 60°C, 
tissue sections were deparaffinized with xylene 2x 5 min, rehydrated with 100% ethanol 2x 3 
min, 90% ethanol 3 min, 80 % ethanol 3 min, 70% ethanol 3 min, and stored in H20. Antigen 
retrieval was done in citrate buffer pH 6,0 in a medical decloaking chamber (Biocare medical). 
Slides were rinsed in TRIS buffer pH 7.6 2x 10 min. Before staining, slides were post-fixed with 
4% paraformaldehyde, rinsed with 0.1% PBS-T 2x 10 min, and permeabilized with 0.3% 
Triton-X100 in PBS for 5min. Slides were washed 3x with PBS-T and blocking of unspecific 
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binding sites was performed using 3% BSA, 10% FBS for 30 min. First antibody was diluted in 
1% BSA solution together with 300 nM DAPI, added in right dilution (see 4.1, table 1. 
antibodies) and incubated overnight at 4°C in the dark. After 3x PBS-T washing steps for 5 min 
each, secondary antibody was added and incubated for 2 hours. Slides were mounted after a 
final 3x washing step on coverslips using fluorescence mounting medium. For control 
staining’s, secondary antibody only (donkey anti-rabbit IgG AlexaFluor647) and normal mouse 
IgG2a Alexa Fluor488 isotype control were added instead of reactive antibodies. Pictures were 
taken on an inverted microscope (Axiovert 40 C; Zeiss; Jena, Germany).  
 ELISA assays 
Cell culture supernatants to measure CCL2 were collected from murine and human cell lines 
after incubation with IC60 deltarasin for 72 hours, or without treatment for validation of efficient 
knockdown of CCL2 in FULA1 cells. Quantitative measurement of natural CCL2 was done 
using sandwich ELISA kits from the Peprotech GmbH company. With this technique an 
antibody pair, capture and detection, is used to bind the antigen from test samples by creating 
the so-called sandwich. The amount of bound biotinylated detection antibody can be quantified 
by adding binding partner avidin, which is conjugated to horseradish peroxidase (HRP)- 
enzymes. By adding ABTS (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt) substrate and its oxidation a green colour change is formed and absorbance 
can be measured which is directly proportional to the amount of protein. For this, 96 well ELISA 
microplates were coated with capture antibody (0.25 µg/ml) overnight. Samples were loaded 
next day undiluted and a standard dilution series. For detection, 0.5 µg/ml detection antibody 
was used. Then Avidin-HRP-conjugate was added for 30 min before ABTS liquid substrate 
was incubated until color development and signal intensity measurement at 405 nm (650 nm 
for background-subtraction) on a microplate reader (TECAN). For normalization of CCL2 levels 
to total cellular protein, whole cellular lysates of same sample as supernatants were prepared 
as described previously using RIPA buffer and quantified using BCA assay kit.  
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Figure 9: Mechanism of sandwich ELISA using the biotin-streptavidin bond and enzymatic reaction of 
HRP and ABTS substrate. Ab, antibody; ABTS, 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt; B, biotin; HRP, horseradish peroxidase; STR, streptavidin.  
 
 Molecular biology methods 
 Proteomics analysis 
For proteomics analysis samples were prepared as following: Either cells or tumor tissue was 
used, 3 biological samples were prepared and then pooled for proteome analysis. The tumor 
tissue was minced into small pieces. The cell lines LLC, FULA1 and PANO2 were either treated 
or not treated with deltarasin IC60 concentrations or 2% DMSO/saline controls for 72 h before 
washing with PBS once. Cells were scraped off in PBS, collected and centrifuged (400G, 10 
min). The tumor tissue or cell pellet was resuspended in 150 µl 6 M GdmCL buffer, sonicated 
for 10min at 4°C with a bioruptor sonication machine (10 cycles à 30 sec sonication, 30 sec 
pause), stored on ice for another 10 min before final centrifugation. A BCA assay was 
performed determining protein concentration and 20 µg/ sample was used for proteome 
analysis conducted by the core facility proteomics of the Helmholtz center Munich. Liquid 
chromatography with tandem mass spectrometry (LC-MSMS) analysis was done on an 
Ultimate3000 nano HPLC system (Dionex, Sunnyvale, CA) online coupled to LTQ OrbitrapXL 
mass spectrometer (Thermo Fisher Scientific). Raw abundances were normalized for factors 
resulting from experimental disparity. A normalization factor is automatically calculated in all 
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samples and over all features correcting all samples in a similar way82. The normalized data 
was used for further analysis. The ratios of treated/ untreated samples, and the ratios of 
KrasMUT/KrasWT samples were produced and final results were compared for finding differently 
expressed proteins in in vitro versus in vivo samples (ratios <0.5 and >2 were considered as 
relevant different expression; fold changes in protein abundance ∆PE).  
 RNA isolation and purification (column and/or ethanol purification) 
Cellular RNA was isolated using Trizol reagent following the manufacturer’s instruction. Further 
purification was done by RNAeasy column kit and genomic DNA removal. Additional ethanol 
purification was used if RNA quality was low. For this 0.1 volume of 3 M sodium-acetate and 3 
volumes of ice-cold 100% ethanol were added to the sample before storing at -80°C overnight. 
After 30 min centrifugation (4°C at 13000 rpm) the day after the pellet was washed twice with 
75% ethanol, air dried and resuspended in water.  
 cDNA synthesis and qPCR 
cDNA synthesis was performed using 1 µg RNA, oligo(dT)18 and iScript Advanced cDNA 
synthesis kit for RT-qPCR in separate tubes. Specific primers for human and murine 
Gapdh/GAPDH and murine and human Il1r1/IL1R1 are listed in table 4. Quantitative PCR 
(qPCR) was performed using Lightcycler 480 Sybr Green I Master in a Lightcycler 480 II. 
Following setting was used to run qPCR:  
Preheating  95°C 
300 sec  95°C 
10 sec   95°C 
20 sec   57°C        45 cycles  
10 sec   72°C 
60 sec   95°C 
∞   4°C 
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Ct values from triplicate reactions were analyzed with the 2-ΔCT method. mRNA abundance was 
determined compared to Gapdh/GAPDH (ΔCT= Ct (Il1r1/IL1R1) – Ct (Gapdh/GAPDH) and is 
given as 2- ΔCT.  
 Microarray analysis 
RNA extraction was performed as described above in triplicate cultures of 106 cells. Five μg of 
pooled total RNA were tested for RNA quality on an ABI2000 Bioanalyzer labelled and 
hybridized to GeneChip Mouse Gene 1.0 or 2.0 ST arrays (Affymetrix; Santa Clara, CA). For 
statistical analysis of differential gene expression (ΔGE), unsupervised hierarchical clustering, 
and WikiPathway analysis, Affymetrix Expression/Transcriptome Analysis Console (TAC) was 
used to normalize all arrays together using Lowess multi-array algorithm and intensity-
dependent estimation of noise (Thermo Fisher Scientific), and finally profile transcriptional 
changes of KrasMUT and KrasWT cell lines normalized to benign cells (whole murine lungs, 
tracheal epithelial cells (TEC), bone marrow-derived macrophages (BMDM), and mast cells 
(BMMC). Microarray data is stored online and available at the GEO 
(http://www.ncbi.nlm.nih.gov/geo/; Accession IDs: GSE130624).  
 GSEA and Kaplan-Meier Analysis 
Gene set enrichment analysis (GSEA) was performed using a free available software provided 
by the Broad Institute (Fig. 10). The following datasets were used for further analysis: 
GSE31852 with gene expression profiles of 121 biopsies from patients with non-small cell lung 
cancer including EGFRMUT (n = 17), KRASMUT (n = 21) or double wildtype control samples 
(n = 83; Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination 
(BATTLE) trial, GEO data portal, https://www.ncbi.nlm.nih.gov/geo/)83. Another comparison 
was made using a subset of the molecular signature database (MSigDB), the 50 hallmarks 
gene set (Broad Institute, see supplementary list 12.3).  
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Figure 10: GSEA analysis overview. GSEA is performed by applying online available datasets to the 
gene list of interest to create enrichment plots. Online available at: 
http://software.broadinstitute.org/gsea/index.jsp (accessed 12 July 2019). 
 
Further downloaded and reanalyzed with the TAC software (Thermofisher Scientific) was 
following dataset: GSE43458 with gene expression profiles of never-smoker (n = 40) and 
smoker (n = 40) LADC, as well as normal lung tissue (n = 30), also from the BATTLE trial84. 
GSE103512 with gene expression profiles of breast (n = 65), colorectal (n = 55), and non-
small-cell lung (n = 60) cancer patients from a Roche dataset was also reanalyzed85. Kaplan-
Meier analysis was done with the free available KM-plotter (http://www.kmplot.com) analyzing 
data from LADC patients (n = 720) compared to SCLC (n = 524)78.  All patients were included 
and overall survival, all stages and grades were set as parameters80.  
 In vivo mice models  
 Study approval 
All mouse experiments were prospectively approved by the Veterinary Administration of 
Western Greece (approval 276134/14873/2) or by the Bavarian regulatory agency (Regierung 
von Oberbayern, approval 55.2-1-54-2532-194-2016) and were conducted according to the 
directive 2010/63/EU.  
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 Mice 
All mice were bred at the Patras Center for Animal Models of Disease. Experiments were 
conducted there. Experimental mice were sex-, weight- (20-30 g), and age- (6-12 weeks) 
matched; both genders were used. In total, 284 mice were enrolled. 25 FVB (21 for tumor 
experiments, 4 as bone marrow donors), 151 C57BL/6, 15 Cxcr1-/- (on  C57BL/6 background), 
34 Ccr2-/- (12 on C57BL/6 and 18 on FVB backgrounds for tumor experiments, 4 on FVB 
background as bone marrow donors), 12 Cxcr2+/- (C57BL/6 background), 32 Rag2-/- (C57BL/6 
background), and 15 Il1b-/- (C57BL/6 background) mice were used80.  
 In vivo tumor formation and drug treatment 
For in vivo injections, 106 cells were diluted in 50 µl PBS and subcutaneously (sc) injected in 
the flank. When tumors reached 100 mm3, drug treatments were initiated and involved daily 
intraperitoneal (ip) injections with saline 1% DMSO or deltarasin (15 mg/Kg in 100 μL saline 
1% DMSO). Tumor dimensions (length, L; width, W; depth, D) were monitored consecutively 
using calipers and the final volume (V) was calculated with following formula: = ∗
∗ ∗ 6⁄ . Animals were monitored daily for health status and were euthanized using CO2 
when tumors reached 2-3 cm3 volume or when in distress, whichever came first. Tumors were 
extracted and fixed in 4% paraformaldehyde overnight before embedded in paraffin for further 
analysis80.  
 Bone marrow transplantation 
FVB wild-type (WT) and Ccr2-/- mice were used for bone marrow transplants (BMT). Ccr2-/- 
mice were total-body irradiated (900 Rad) before receiving 10x106 bone marrow (BM) cells 
intravenously (iv) 12 hours later36,41,43. BM cells were collected from WT and Ccr2-/- mice by 
flushing femur and tibia bones using full growth media DMEM (post >F12 back-crossing to the 
FVB background). After irradiation and BM cell receive, mice could recover for full bone marrow 
reconstitution for 30 days before implanting flank tumors with 106 FULA1 cells dissolved in 50 
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µl PBS and further deltarasin treatment. One mouse per experiment was not engrafted for 
observation till moribund on day’s 5-15 post-irradiation.  
  Statistics 
Mouse sample size was calculated using G*power (http://www.gpower.hhu.de/)76. Significant 
differences (biologically (> 50%) and statistically (α = 0.05; β = 0.20)) between values from 
individual mice with SD ~ 30% of mean were analyzed using the two-tailed t-tests, yielding n 
= 7/group. Experiments with n = 5/group were contemplated in batches, till the achievement of 
probability (P) < 0.05 with α < 0.05 or P > 0.05 with β < 0.20, whichever came first. Two-way 
ANOVA was employed to analyze the data. Significant differences in cellular assays were 
assessed using one-way or two-way ANOVA with Bonferroni post-tests. IC50 values were 
calculated using nonlinear regression analysis comparing data points by extra sum-of-squares 
F-test. Fisher’s exact test for cross-tabulation was performed presenting significance between 
drug sensitivity and resistance in Kras/KRASWT/MUT cell lines. Significance was considered 
when values were < 0.05 (*), < 0.01 (**), and < 0.001 (***). Values are shown as mean ± SD. 
Sample size (n) states biological replicates. Statistics and plots were done on GraphPad Prism 
software 5.0 and 6.0 (GraphPad; San Diego, CA)80. 
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6. Results 
 Primary in vitro resistance of KRAS inhibitors 
We investigated the cellular response of a panel of murine (n = 5 - 7) and human (n = 3 -  9) 
Kras/KRAS-mutant (KRASMUT in further text) or Kras/KRAS-wildtype (KRASWT in further text) 
cancer cell lines (Figure 11A, B) to three pre-clinical KRAS inhibitors: The widely used drug 
deltarasin targeting KRAS transport protein PDEδ, the KRASG12C-specific inhibitor AA12, and 
ICMT inhibiting cysmethynil (Figure 3A)47,49,51. For this purpose, the most common assays were 
employed based on literature searches, such as MTT and colony formation assay (Figure 
11C). Initially, IC50 values were calculated via analysis of cell viability using WST-8 assays after 
72 hours of drug treatment as readout (Fig. 12A-D). For this half-log-incremental drug 
concentrations were applied. We were not able to achieve significant differences regarding 
KRAS mutation status by none of the used inhibitors. Of the 16 cell lines tested, detectable 
significant differences concerning KRAS mutation status were only in four cell lines (LLC 
(KrasG12C), MC38 (KrasG13R), A549 (KRASG12S), and H1944 (KRASG13D)) with inhibitor 
deltarasin and only one cell line (A549) with significant IC50 differences after cysmethynil 
treatment. Importantly, the concentration range to generate in vitro efficacy was modest and 
fluctuated between 1 - 50 µM. In this context a literature research using PUBMED highlighted 
a massive disparity between FDA-approved tyrosine kinase inhibitors and preclinical inhibitors 
against KRAS (Figure 11D). While successful inhibitors showed drug doses under 100 nM to 
achieve efficacy in preclinical in vitro assays and did enter the clinic, KRAS inhibitors are only 
effective with much higher concentrations.  
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Figure 11: List and information of cell lines used for this dissertation, frequently published in vitro assays 
in cancer research and comparative preclinical efficacy of KRAS versus tyrosine kinase inhibitors (TKI). 
(A) Mouse cell lines with their syngeneic mouse strain, originated tissue, and mutation status of three 
genes of interest. Data from reference list under 12.1, S1-S6. (B) Human cell lines and information to 
mutation status and originated tissue. Data from 12.1, S7. (C) Summary of cellular assays in 
correspondence to target gene and cancer research. PubMed search done on 17.07.2017 using the 
terms “assay type” AND “gene” AND “cancer”. MTT,3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; MTS,3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium); ATP, adenosine triphosphate; LDH, Lactate dehydrogenase; BrdU, bromodeoxyuridine, 5-
bromo-2'-deoxyuridine. Data shows number of retrieved publications as readout. (D) Fifty percent 
inhibitory concentrations (IC50) of selected FDA-approved TKI; top) compared to preclinical KRAS 
inhibitors (bottom). Note the statistically significantly higher IC50 of KRAS inhibitors compared with TKI. 
Data source see supplementary reference list under 12.2, S8-S25. n = 1-4 published studies; P, overall 
probability by 2-way ANOVA. Figure modified from Arendt et al.80.  
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Figure 12: Primary resistance of KRAS-mutant tumor cells to KRAS inhibitors in vitro. Different mouse 
tumor cell lines (KrasMUT: LLC, MC38, AE17, FULA1; KrasWT: B16F10, PANO2) and human tumor cell 
lines (KrasMUT: A549, H460, H358, H358M, H1944, HOP-62; KrasWT: EKVX, H1299, H3122, H520) were 
assessed for cell viability (determined by WST-8 assay, point mutations are presented in parentheses). 
n = 3-5/cell line. (A-C) Representative sigmoidal curves of murine (left) and human (right) cell lines 
treated with increasing doses of deltarasin, AA12, or cysmethynil for 72 hours. n = 3/data point. (D-F) 
Averages of 50% inhibitory concentrations (IC50, µM) of deltarasin, AA12, and cysmethynil on cell viability 
cancer cell lines. Mean (all cell lines tested), shown in grey lines, was used to separate sensitive and 
resistant cell lines. Note no significant differences regarding Kras mutation status. n = 3-5/data point. 
Data presented as mean ± SD. P, overall probability by nonlinear fit and extra sum of squares F-test (A-
C) or by Fisher’s exact test for cross-tabulation of Kras/KRAS mutation status to drug 
sensitivity/resistance. (D-F). Figure modified from Arendt et al.80.  
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To solidify the in vitro results, we analyzed the response of murine (n = 4) and human (n = 4) 
cell lines to IC60 values of deltarasin via colony formation assay (Fig. 13A, B). Again, incubation 
with the KRAS blocker reduced the proliferation and formation of colonies independent of 
KRAS mutation status and not as expected specifically in KRASMUT cell lines (analyzed on 
basis of counted total colony formation and plating efficiency, supplementary Fig. S1). The 
human KRASWT cell lines H3122 and EKVX were even stronger inhibited after drug incubation.  
Since KRAS activates MAPK cascade inducing phosphorylation of ERK, we measured and 
quantified p-ERK/ GAPDH and t-ERK/ GAPDH via western blot in murine (n = 6) and human 
(n = 6) cell lines treated with saline or IC60 concentrations of deltarasin for 72h. Unexpectedly, 
deltarasin achieved an overall downregulation of the p-ERK signal independent from KRAS 
mutation status (Fig. 13C, D, supplementary Fig. S2). Thus, two additional assays 
strengthened our hypothesis that KRAS drugs fail specific in vitro inhibition.  
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Figure 13: Unspecific response of Kras/KRASMUT tumor cells to deltarasin in vitro. Multiple mouse and 
human cancer cell lines with (red) and without (black) Kras/KRAS mutations (point mutations shown in 
parentheses) were evaluated for colony formation by crystal violet (CV) staining and for ERK 
phosphorylation by phospho (p)- and total (t)-ERK immunoblots after 72 hours treatment with IC60 
concentrations of deltarasin. (A) Representative images of CV stained colonies treated with deltarasin 
or saline. (B) Colony survival fraction of human and murine cell lines after IC60 deltarasin and 3–5 days 
culture. Values represent data from two independent experiments (n = 3/experiment). (C) Quantification 
of normalized p-/t- ERK signal. (D) Representative immunoblots of 72 hours treated cell lines with 
deltarasin or saline and p-ERK, t-ERK and GAPDH signals. Protein lysates pooled from 3 independent 
treatment experiments. Data presented as mean ± SD. P, probability by Fisher’s exact test for cross-
tabulation of Kras/KRAS mutation status to drug sensitivity/resistance. Figure modified from Arendt et 
al.80.  
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 Specific in vivo results of small molecule KRAS inhibitor deltarasin  
In parallel to in vitro studies we induced sc tumors in FVB, C57BL/6, and Rag2-/- mice with 
KRASMUT cell lines LLC (KrasG12C), FULA1 (KrasQ61R) or H460 (KRASQ61H) and treated mice 
daily with deltarasin ip (15 mg/Kg) or saline after tumor development (start of treatment: tumor 
volume ≥ 100 mm3 and at least 10 days latency post sc injection). The dose was thereby 
chosen based on literature research and validation done by Zimmermann et al49. Surprisingly, 
the drug significantly reduced tumor growth harboring a KRAS mutation, but not tumors 
generated from KRASWT cell lines B16F10, PANO2 or EKVX (Fig. 14A, B). Therefore, we 
hypothesized that deltarasin induced KRAS inhibition depends on an in vivo surrounding and 
is not reproducible in basic cellular assays. 
  
Figure 14: Selective KRAS mutation efficacy of deltarasin in vivo. Murine and human tumor cell lines 
with (A; KRASMUT: LLC, FULA, H460) or without (B; KRASWT: B16F10, PANO2, EKVX) Kras/KRAS 
mutations (codon change in parentheses) were sc injected in the murine flank (106 tumor cells) of 
C57BL/6, FVB, or Rag2-/- mice. Daily ip injections of saline or 15 mg/Kg deltarasin after tumor 
development > 100 mm3 size. Tumor growth is significantly reduced in KRASMUT tumors. Data presented 
as mean ± SD. n, sample size stated in the figure; P, 2-way ANOVA and Bonferroni post-test; ns, *, **, 
***, and ****: P > 0.05, P < 0.05, P < 0.01, P < 0.001, and P < 0.0001.  
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 Opposing dependencies in vitro and in vivo in genetic modified KRAS models 
To further validate the in vivo restricted role of hyperactive KRAS we overexpressed either 
shRNA (shKras) in murine KrasMUT cell lines or pKrasG12C plasmid (plasmid maps see 
supplementary Fig. S3) in KrasWT cell lines41. These genetic manipulated cell lines were 
validated on RNA and protein levels, monitored over 150 hours in culture and studied with MTT 
reduction assays by colleagues 201741. They showed that mutant KRAS does not affect cell 
viability in vitro. In accord with our inhibitor studies, genetic Kras intervention did not achieve 
a mutation specific effect to deltarasin, determined by IC50 value calculation after 72 hours of 
drug incubation in vitro, followed by cell viability assays (Fig. 15A, B). Only one out of six cell 
lines showed a significant reduction of cell viability, but with opposite effect. Deltarasin was 
effective in the shKras MC38 cell line and not in the parental MC38 harboring a KrasG13R 
mutation. Additionally, we used the parental wildtype human cell lines EKVX and H3122 and 
overexpressed mutant KRAS by transfection of the pKRASG12C plasmid (validation in 
Supplementary Fig. S4). Transfection did not change the response to different concentrations 
of deltarasin on cell viability, as expected (Fig. 15A, C). Furthermore, the analysis of ERK 
phosphorylation revealed no ERK activation after Kras/KRAS modulation. Knockdown of 
hyperactive KRAS with shRNA does show a slight reduction in p-ERK signal, but introduction 
of pKrasG12C does not increase it (Fig. 15D, E; supplementary Fig. S5). In summary, our in vitro 
observations done with three preclinical KRAS inhibitors, and using three different in vitro 
assays showed no consistent KRAS dependency. Of seven genetic modified cell lines only 
one cell line showed the expected result after deltarasin treatment in the WST-8 assay (MC38 
shKras). Only 36% of the Kras/KRASMUT murine and human cell lines responded to deltarasin 
and only 17% to cysmethynil. Downregulation of ERK phosphorylation and decrease in colony 
formation by deltarasin treatment was achieved irrespective of mutant KRAS status in both 
genetic modified cell lines and parental Kras/KRASMUT or Kras/KRASWT cells. Thus, in vitro 
systems are not optimal to study KRAS and to develop effective inhibitors. 
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Interestingly, the same genetic modified cell lines showed significant capability to reduce tumor 
growth in vivo: shKras knockdown in murine cell lines displayed a strong tumor growth 
decrease over time compared to unmodified cell lines (50-90% biological and statistical (P < 
0.001) inhibition). Vice versa, introduction of pKrasG12C increased the tumor growth rate 
drastically (Fig. 17A, B). Deltarasin tested in PANO2 pKrasG12C- and EKVX pKrasG12C-flank 
tumors had a very good drug response compared to parental cell lines (Fig. 17C). Collectively, 
these experiments support our findings of inhibiting KRAS pharmacologically. Again, tumor 
growth seems to be selectively inhibited in vivo.  
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Figure 15: Genetic manipulation of Kras/KRAS shows no dependency in vitro. (A) Representative 
sigmoidal curves of different murine and human cell lines with Kras/KRAS modification treated with half-
log concentrations of deltarasin to assess cell viability after 72 hours of drug treatment. n = 3/data point. 
(B) IC50 concentrations of deltarasin treatment in parental (black: stably expression of random shRNA 
or control plasmid pC) or Kras-modified (red: stably expression of shKras RNA; green: stably expression 
of mutant KRASG12C plasmid) tumor cell lines (n = 2-4/data point by independent experiments). (C) 
Human parental (black: stably expression of control plasmid pC) or Kras-modified (green: stably 
expression of mutant KRASG12C plasmid) tumor cell lines were assessed for cell viability (determined by 
WST-8 assay, n = 2 - 5/ data-point) after 72 hours of drug treatment. (D) Exemplary immunoblots of cell 
lines for p-ERK, t-ERK and GAPDH. Protein lysates pooled from 3 independent experiments. (E) 
Quantification of normalized p-ERK/t-ERK signal after normalization to GAPDH. Individual data points 
were summarized by mutation status (red: KRASMUT; black: KRASWT) and origin (n = 2-3). P, overall 
probability by nonlinear fit and extra sum of squares F-test (A) or one-way (B, C) and two-way (E) 
ANOVA. ns and **: P > 0.05 and P < 0.01, respectively, for the indicated comparisons by Bonferroni 
post-tests. Data are presented as mean ± SD. Figure modified from Arendt et al.80. 
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Figure 16: Summary of in vitro experiments grouped by species (human and murine) and Kras/KRAS 
mutation status. (A) Summary of IC50 values of three KRAS inhibitors deltarasin (n = 3,3; 5,4), AA12 (n 
= 2,3; 2,2), and cysmethynil (n = 4,2; 2,2) determined by WST-8 assay. (B) Summary of colony formation 
assay after deltarasin treatment (n = 2,2; 2,2) (C) Summary of western blot analysis and quantification 
of p-ERK and t-ERK relative to GAPDH (n = 4,2; 4,2). (D) Summary of IC50 values of genetic modified 
cell lines treated with deltarasin and determined by WST-8 assay (n = 5,5; 2,2). P, overall probability by 
two-way ANOVA. ns: P > 0.05 for the indicated comparisons by Bonferroni post-tests. Data are 
presented as mean ± SD. n = murine KrasMUT, KrasWT; human KRASMUT, KRASWT cell lines.  
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Figure 17: Genetic manipulation of Kras shows high dependency in vivo. C57BL/6 mice harboring flank 
tumors of genetic modified murine cells ((A) shKras; red, (B) pKrasG12C; green) or control cells (shC, pC; 
black) were grown over time and monitored (right: graphic of the effect of genetic Kras intervention by 
shRNA downregulation, red; or plasmid overexpression, green). (C) PANO2 and EKVX overexpressing 
Kras mutant plasmid pKrasG12C (Left: graphic of the introduced plasmid containing KRASG12C, GFP, and 
PUROMYCINR sequences), were injected in the murine flank (106 tumor cells sc) of either C57BL/6 or 
Rag2-/- mice. Daily ip injections of saline (black) or 15 mg/kg deltarasin after tumor development > 100 
mm3 size. Data presented as mean ± SD. n, sample size stated in the figure; P, 2-way ANOVA and 
Bonferroni post-test; ns, *, **, ***, and ****: P > 0.05, P < 0.05, P < 0.01, P < 0.001, and P < 0.0001. 
Figure modified from Arendt et al.80. 
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 Exclusive in vivo development of secondary resistance 
A common response of targeted therapy is the development of secondary resistance. We 
detected these trends in LLC and FULA1 induced flank models post day 28 of daily ip treatment 
with deltarasin (Fig. 18A). Therefore, we wanted to test the reproducibility of this effect in vitro 
by constantly treating both cell lines with the IC60 concentration of the drug over the time of 22 
weeks (Fig. 18B). Changes in cell viability were tested at week 1, 12 and 22 via repeating cell 
viability assays. At all three time points IC50 values were in the same range. This indicates an 
unresponsiveness of monolayer plated cell lines to the drug. We established primary cell lines 
from flank tumors of LLC and FULA1 from control, sensitive, and resistant mice (≥ 28 days 
treatment, highlighted by arrows Fig. 18A). These cell lines were isolated and directly tested 
to their drug response in vitro. Expectedly, we were not able to detect similar drug responses 
in these cell lines, which behaved strongly different in vivo (Fig. 18C). These results present 
the strong mutant specific in vivo effect achieved by deltarasin, which vanishes immediately if 
the in vivo setting is lost and cannot be reproduced with basic cellular assays. 
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Figure 18: Development of secondary resistance in vivo is not reproducible in vitro. (A) C57BL/6 mice 
with growing flank tumors from 106 sc LLC or FULA1 cell injection (KrasMUT) were treated daily with ip 
saline or deltarasin (15 mg/kg) and developed secondary resistance on day 25 to 30. Arrows indicate 
timepoints (red: early drug sensitive state, dark red: late drug resistant state) of extracted tumors for 
further development of cell lines from different mice (n = 1 per state). (B) FULA1 and LLC cells were 
treated constantly with IC60 deltarasin concentrations for 22 weeks and response to the drug was 
monitored during WST-8 assay on week 1, 12, and 22 (n = 3). No altered drug response measurable. 
(C)  Extracted tumor cells were passaged 2-3 times and response to deltarasin was evaluated using 
WST-8 assay (n = 3) of saline treated, deltarasin sensitive and deltarasin resistant tumor cells. Data 
presented as mean ± SD. P, overall probability by two-way ANOVA for the indicated comparisons by 
Bonferroni post-tests. 
 
 High expression of Ccl2 and Il1r1 in Kras-mutant transcriptome profile 
Trying to answer the question which mediators are responsible for the in vivo only dependency 
to mutant Kras, we analyzed the transcriptome of parental as well as Kras-modulated cell lines 
and benign samples [bone marrow-derived macrophages (BMDM), mast cells (BMMC) whole 
lungs, and tracheal epithelial cells (TEC)].  
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Figure 19: A 42-gene KRAS dependent signature containing inflammatory mediators Ccl2 and Il1r1. (A) 
Unsupervised hierarchical clustering of gene expression of KrasMUT (n = 4), KrasWT cells (n = 4) and 
benign cells and tissue (n = 4). (B) Analytical strategy of the transcriptome analysis explained as Venn 
diagram. (C) Unsupervised hierarchical clustering of gene expression of genetic modified cell line 
doublets (shKras versus pKrasG12C) reveals correlation of Il1r1 and Ccl2.; P, family-wise error rate 
probability; n = 2 for every single cell line. Figure modified from Arendt et al.80. 
 
Unsupervised hierarchical clustering with all parental cell lines showed absolute segregated 
clustering of KrasMUT cell lines, KrasWT cell lines and benign samples (1408 differentially 
expressed genes (ΔGE) using an ANOVA P < 0.05 threshold, Fig. 19A). By paired analysis of 
genetic modified cell lines (LLC, MC38, and AE17 shC versus shKras and PANO2 and B16F10 
pC versus pKrasG12C) with isogenic cell line doublets, we detected another 3432 Kras-
responsive transcripts.  
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Out of 170 transcripts that were present in both gene sets and by excluding every ambiguous 
gene expression, we ended up with a profile including 32 upregulated genes and 10 
downregulated genes regulated by mutant Kras (ΔGE > 1.40, Fig. 19B). Interestingly, it 
contained inflammatory modulators like Ccl2, Ccl7, Cxcl1, and Il1r1 and revealed a tight 
correlation of these mediators (Fig. 19C). Using WikiPathway analysis and the murine pathway 
database we found a strong probability of our KrasMUT expression profile in chemokine 
signaling (Fig. 20A)75. To proof the relation to human data, we next translated the murine genes 
to 37 human orthologues using Orthoretriever (https://www.orthodb.org/and) and run GSEA 
(http://software.broadinstitute.org/gsea/index.jsp)74. A comparison to the Broad institute’s 50 
hallmark signature including gene sets of angiogenesis, PI3K-AKT-MTOR signaling, and DNA 
repair, revealed a highly positive enrichment in only one signature, the “inflammatory 
response” and negative in the “G2M- checkpoint“signature (Fig. 20C, D, supplementary list 
12.3 for full hallmark gene list)86. Moreover, we used a BATTLE trial dataset consisting of 
microarray data from 21 KRASMUT and 17 EGFRMUT NSCLC patient samples (GSE31852), in 
which the KRASMUT profile was significantly positive enriched in KRAS-mutant LADC only, 
validating our KrasMUT specific genes in a human cohort (Fig. 20B)83. These results led to the 
assumption that proinflammatory signals are responsible for in vivo restricted inhibition of 
KRASMUT lung cancer.  
 CCR2+ myeloid cells secreting IL-1ß as key players of in vivo KRAS- 
dependence  
Next, we wanted to test the importance of CCR2+ IL-1β- secreting myeloid cells for KRASMUT 
tumors. Immunofluorescence staining’s of murine and human tumor tissue by 
immunofluorescence visualized co-existence of IL-1β and CCR2 in the tumor tissue (Fig. 21, 
22).  
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Figure 20: Correlation of 37 human homologs of the Kras-specific genes with signaling pathways. (A) 
Wikipathway analysis showing chemokine signaling overrepresented in the KRAS signature. (B) GSEA 
analysis of 37 human orthologues against BATTLE dataset containing KRASMUT (n = 21) and EGFRMUT 
(n = 17) LADC samples reveals strong correlation to human KRASMUT signature. (C) Top: GSEA of 37 
human orthologues shows more positive enrichment in “inflammatory response” compared to negative 
enrichment (D) in “G2M checkpoint” (Broad Institute’s 50 hallmark signatures). NES, normalized 
enrichment score; P, family-wise error rate probability. Figure modified from Arendt et al.80.  
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Figure 21: Immunofluorescence images of tumor tissue sections. Murine tumors were established 
through sc injection of 106 tumor cells (FULA1 or PANO2) and extracted from these allograft flank 
models (C57BL/6 and FVB mice). Immunofluorescence stainings for IL-1β (Alexa488) and CCR2 
(Alexa647). Bar = 50 µm. Secondary antibody control stainings see supplementary figure. S7.  
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Figure 22: Immunofluorescence images of tumor tissue sections. Human tumors were established 
through sc injection of 106 tumor cells (H460 or EKVX) and extracted from these xenograft flank models 
(Rag2-/- mice). Immunofluorescence stainings for IL-1β (Alexa488) and CCR2 (Alexa647). Bar = 50 µm. 
Secondary antibody control stainings see supplementary figure S7.  
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To proof our hypothesis, we used syngeneic C57BL/6 mice deficient (Il1b-/-, Ccr2-/-) in the Il1b 
and Ccr2 genes or competent (WT) mice to induce flank tumors induced with sc injection of 
LLC cells (KrasG12C). Response to daily ip deltarasin (15 mg/Kg) or saline treatment (after tumor 
size ≥ 100 mm3) was monitored bi-weekly. As seen before deltarasin was able to reduce 
statistically and biologically significant tumor growth in WT mice (Fig. 23A). Surprisingly, 
KrasMUT- specific deltarasin effect was completely depleted in Ccr2-/- and highly reduced in Il1b-
/- mice (Fig. 23B). No changes were displayed in chemokine-receptor-knockouts Cxcr1-/- and 
Cxcr2+/- mice (Fig. 23C).  
To eliminate the option of developmental effects of knockout mice, we used a bone marrow 
transplant (BMT) experiment using syngeneic FVB mice (Ccr2-/- and WT mice back-crossed > 
F12 to the FVB strain) and FULA1 cells (KrasQ61R). This allowed us to gather results with 
another cells line and a different Kras mutation, as well as broaden the spectrum of mutations 
closer to human LADC. We next irradiated (900 Rad) Ccr2-/- mice to erase all bone marrow 
(BM) cells. On this background we injected BM from either WT or Ccr2-/- donors. After recovery 
time of 30 days FULA1 cells were sc injected and established flank tumors (≥ 100 mm3) were 
treated as usual with daily ip deltarasin or saline. Expectedly, Ccr2-/- with BM from the same 
knockout mice did not respond to drug treatment as shown before (Fig. 23B right, 24A right). 
Instead, Ccr2-/- chimeras with WT BM reproduced the original statistically and biologically 
significant drug effect seen in wildtype mice (Fig. 23A, 24A left). Taken together, these results 
specify that CCR2+ myeloid cell recruitment is required for deltarasin efficacy against Kras-
mutant tumors in vivo. To develop a different tumor model, we transfected FULA1 cells with 
shRNA against CCL2 to downregulate its expression. Cell clones were selected with 
puromycin and then picked. Validation was done with ELISA using supernatants of 5 clones 
(shControl and shCCL2). CCL2 expression is significantly downregulated under shCCL2 
expression and these cell clones will be used for further experiments in the future Fig. 24B).  
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Figure 23: Selective efficacy of the KRAS inhibitor deltarasin depends on host CCR2 and IL1B. 106 LLC 
cells (KrasG12C) were injected sc for Kras mutant tumor establishment in the rear flank of different 
knockout mice with C57BL/6 background. Tumor volume was monitored during daily ip injections of 
saline (black) or 15 mg/kg deltarasin after tumor development to 100 mm3 size. (A) Exemplary image of 
CCR2/IL-1β-co-staining of a KRAS-mutant tumor from a Rag2-/- mouse presenting co-localization in the 
tumor stroma. (B) Syngeneic C57BL/6 wildtype mice with KRASMUT tumors showing efficacy of 
deltarasin treatment. (C) Il1b-/- and Ccr2-/- deficient mice harboring KRASMUT tumors grew similar in both 
treatment and saline groups. (D) Deltarasin treatment in Cxcr1-/- and Cxcr2+/- mice with KRASMUT tumors 
significantly reduced tumor growth alike wildtype C57BL/6 mice. In brackets: Percentile tumor inhibition 
by deltarasin compared with saline. n, sample size stated in the figure. Data are presented as mean ± 
SD. P, overall probabilities by 2-way ANOVA; ns, *, **, ***, and ****: P > 0.05, P < 0.05, P < 0.01, P < 
0.001, and P < 0.0001.  
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Figure 24: Kras-mutant cancer cells require host Ccr2 signaling, which can be disturbed by deltarasin 
mediated IL1R1 expression downregulation. (A) Ccr2-/- mice were total-body irradiated with 900 Rad 
before receiving adoptive BMT from WT (black, left graph) or Ccr2-/- (black, right graph) donors (back-
crossed > F12 to the FVB strain). One month later both chimera groups received sc 106 syngeneic 
FULA1 cells (KrasQ61R). Daily ip saline or deltarasin (15 mg/Kg, red) treatments were started when 
tumors grow > 100 mm3. n, sample size stated in the figure. Data presented as mean ± SD. P, 2-way 
ANOVA and Bonferroni post-test; ns, *, **, ***, and ****: P > 0.05, P < 0.05, P < 0.01, P < 0.001, and P < 
0.0001. (B) FULA1 cells were transfected with shCCL2 or shC mRNA to downregulate CCL2 expression. 
Validation of positive knockdown done with supernatants of transfected cell lines and ELISA to quantify 
secreted CCL2 levels. n = 5 samples/group; Data presented as mean ± SD. P, unpaired t-test. *: P < 
0.05. Figure modified from Arendt et al.80.  
 
 Deltarasin disrupts IL-1β sensing in KRAS-mutant tumor cells 
From the microarray-derived KrasMUT signature including Ccl2 and Il1r1 (Fig. 18B) and previous 
reports of KRASMUT-mediated CCL2 and IL1R1 transcriptional regulation we wanted to 
investigate the underlying signaling pathway30,36,79. To gain these insights in the mechanism of 
in vivo specific deltarasin dependence, we validated the expression of Il1r1/IL1R1 mRNA and 
CCL2 protein levels (using LLC, PANO2, H460, EKVX post 72 hours deltarasin treatment) via 
qPCR and ELISA. Indeed, murine and human Kras/KRASMUT cancer cell lines displayed 
strikingly increased Il1r1/IL1R1 mRNA expression related to Kras/KRASWT cell lines. 
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Furthermore, deltarasin treatment significantly downregulated Il1r1/IL1R1 transcript levels 
(Fig. 25A). However, Kras/KRASMUT cell lines demonstrated increased and decreased 
secretion of CCL2 after deltarasin compared with Kras/KRASWT cell lines, suggesting that the 
bulk of in vivo deltarasin effect is mediated via downregulation of Il1r1/IL1R1 expression (Fig. 
25B).  
 
Figure 25: Deltarasin treatment decreases Il1r1/IL1R1 mRNA expression consistently in KrasMUT cell 
lines but has different effects on CCL2 secretion. (A) mRNA expression of Il1r1/IL1R1 done by qPCR 
and (B) protein secretion of CCL2 done by ELISA. Mouse (left) and human (right) cancer cell lines were 
treated for 72 hours with saline or deltarasin IC60 concentrations. n = 3; data presented as mean ± SD. 
P, overall probabilities by 2-way ANOVA; ns, *, and ***: P > 0.05, P < 0.05 and P < 0.001, respectively, 
for the indicated comparisons by Bonferroni post-tests. Figure modified from Arendt et al.80.  
 
 KRAS/CCL2/IL1B signature in human cancers  
To analyze the significance of our findings to KRASMUT human cancers, we evaluated the 
average gene expression of KRAS/CCL2/IL1B in a clinical cohort of smoker LADC (n = 40), 
never-smoker LADC (n = 40), and normal lung tissue samples (n = 30; GSE43458), public 
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data of the BATTLE trial84. Comparing never-smokers’ LADC and normal lung tissue samples 
with smokers’ LADC we found that overall KRAS/CCL2/IL1B expression was significantly 
increased (Figure 26A). In particular, we found higher expression of IL1B in smokers versus 
never-smokers, CCR2 in smokers versus normal lung tissue and versus never-smokers, and 
IL1R1 in smokers versus normal lung tissue. As a fact, KRAS mutations occur more frequent 
in LADC smoker87. This finding suggests that, in tumors harboring higher KRAS mutation rates 
the inflammatory signature is overrepresented. This was repeatable in a second dataset 
including patients with breast (n = 65), colorectal (n = 55), and lung cancer (n = 60; 
GSE103512), where overall KRAS/CCL2/IL1B expression was significantly higher in colorectal 
and lung cancer, which have high KRAS mutation frequencies, compared with breast cancer 
(Figure 26B)85. 
Assuming, that this inflammatory signaling loop is responsible for the exclusive in vivo specific 
KRAS inhibition, we run online Kaplan-Meier analyses (http://www.kmplot.com) using lung 
cancer patient data cohorts (Fig. 26C)78. Comparing KRAS/CCL2/IL1B expression levels in 
LADC (a tumor type proven to have high KRAS mutation frequency; n = 720) and SQCLC (a 
tumor type proven to have low KRAS mutation frequency; n = 520) showed that LADC patients 
with high expression of the three genes of interest showed poor survival compared to low 
expressers with a hazard ratio (HR) increase of 1.93. On the contrary, the survival curves of 
SQCLC were not impacted by the expression levels. When we looked exclusively at smokers 
only [meaning that looking at even higher KRAS mutation frequencies (26.5% versus 
33.7%,88) ], HR increased in LADC up to 2.28, whereas patient survival in SQCLC data did not 
change. These data collectively suggest that human KRASMUT cancers are affected by the 
KRAS/CCL2/IL1B loop through overexpressing it and thereby controlling survival. Moreover, 
this shows the clinical relevance of these inflammatory signaling mediators as possible new 
targets.  
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Figure 26: The KRAS/CCL2/IL1B axis is overexpressed in KRASMUT cancers and forecasts poor 
survival. (A) Average and normalized KRAS/CCL2/IL1B expression in LADC patient samples from 
smokers, never-smokers and normal lung tissue from never-smokers (BATTLE study GSE43458). (B) 
Normalized KRAS/CCL2/IL1B expression in breast, non-small cell lung, and colorectal cancer (ROCHE 
study GSE103512). KRAS mutation frequency numbers are from COSMIC: 
https://cancer.sanger.ac.uk/cosmic89. (C) Kaplan-Meier analyses done on http://www.kmplot.com78, of 
lung cancer patients focusing on mean expression of KRAS, CCL2, and IL1B. Top: Poorer survival of 
lung adenocarcinoma patients with high expression shown in red (left, HR = 1.93) compared to SQCLC 
patients (right, HR = 0.84). Bottom: HR increases in ever- smokers only patients with lung 
adenocarcinoma while staying the same in SQCLC. P, overall probability by one-way ANOVA. ns, *, **, 
and ***: P > 0.05, P < 0.05, P < 0.01, and P < 0.001, respectively, for the indicated comparisons by 
Bonferroni post-tests. Figure modified from Arendt et al.80.  
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 Other synthetic lethality partners for KRAS 
The transcriptome analysis done with murine KrasWT and KrasMUT cell lines and benign samples 
revealed not only Ccl2 and Ilir1 as possible targets, but also other genes of interest: Ranbp3l, 
Gpr149, Cfap69, Ccl7, 2810417H13Rik, Pdgfra, Casp3, Ttk, Kif2c, Fanca, Cdca5, Rassf8, 
Hist2h3c2, Plag1, Nadk2, Oaf, Cxcl1, Mmd, Csgalnact1, Clybl, Zfp334, Kras, Palb2, Kcnab3, 
Mcts2, Pcnxl4, Gmnn, Poc1a, and Dhx40 were upregulated; Pde8a, Smpdl3a, mt-Tn, mt-Tt, 
Anxa6, mt-Ty, Mapkapk3, Gm2a, mt-Te, and Bmyc were downregulated. We started validation 
of Caspase 3 (Casp3), since it is involved in a cancer-specific pathway, the compensatory 
proliferation, which could explain the in vivo only effect of KRAS inhibition. Therefore, we used 
two Caspase inhibitors, BV6 and Z-DEVD-FMK. The latter is an irreversible Caspase3, -6, -7, 
-8, and -10 inhibitor. BV6 is an inhibitor of the IAP proteins (inhibitor of apoptosis), which 
autocatalyzes and activate the downstream effector caspase3. After validating the IC50 values 
of the two inhibitors in 8 cell lines (KrasMUT: LLC, FULA1, KRASMUT: A549, H460; KrasWT: 
PANO2, B16F10; KRASWT: H3122, EKVX) with WST-8 assays, a combination of increasing 
deltarasin concentrations and IC25 doses of either BV6 or Z-DEVD-FMK were applied for 72 
hours. While Z-DEVD-FMK showed no effect without deltarasin or in combination, the 
combination with BV6 showed highly significant decrease in cell viability of both wildtype and 
mutant cell lines (Fig. 27, 28).  
A proteomics analysis similar to the transcriptomics analysis was performed using two Kras-
mutant cell lines (LLC, FULA1) compared to one Kras-wildtype cell line (PANO2). The 
proteome changes induced by deltarasin treatment (IC60, 72h) of the three cell lines were 
analyzed and compared to deltarasin induced changes in the complement tumor tissue 
samples gathered from in vivo allograft flank models. Strict filtering revealed two proteins 
upregulated in deltarasin treated KrasMUT cell lines and downregulated in the in vivo produced 
protein lysates: CSN9 and CPT1A. One protein was regulated vice versa: K1C16 (Fig. 29A, 
B). CSN9 and CPT1A showed decreased overall survival in lung cancer patients when the 
gene of interest is higher expressed (Kaplan-Meier analysis, Fig. 29C).  
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Figure 27: Inhibitor combination of deltarasin (KRAS specific) and BV6 (Caspase specific). (A) IC50 
values of BV6 compared to deltarasin in murine and human cell lines determined by WST-8 assay, and 
after 72 h of incubation and accelerating drug combinations. (B) IC50 values of BV6 + deltarasin 
compared to deltarasin in murine and human cell lines determined by WST-8 assay after 72 h of 
incubation. IC25 BV6 doses (3 µM for murine cell lines, 6.5 µM for human cell lines) were added to 
accelerating deltarasin concentrations. n = 2-5; P, overall probability by one-way ANOVA. ns, *, **, *** 
and ****: P > 0.05, P < 0.05, P < 0.01, P < 0.001, and P < 0.0001, respectively, for the indicated 
comparisons by Bonferroni post-tests. Data are presented as mean ± SD.  
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Figure 28: Inhibitor combination of deltarasin (KRAS specific) and Z-DEVD-FMK (Caspase specific). (A) 
IC50 values of Z-DEVD-FMK compared to deltarasin in murine and human cell lines determined by WST-
8 assay, and after 72 h of incubation and accelerating deltarasin combinations. (B) IC50 values of Z-
DEVD-FMK + deltarasin compared to deltarasin alone in murine and human cell lines determined by 
WST-8 assay after 72 h of incubation. IC25 Z-DEVD-FMK doses (12 µM for murine cell lines, 22 µM for 
human cell lines) were added to accelerating deltarasin concentrations. n = 2-5; P, overall probability by 
ne-way ANOVA. ns, *, **, *** and ****: P > 0.05, P < 0.05, P < 0.01, P < 0.001, and P < 0.0001, 
respectively, for the indicated comparisons by Bonferroni post-tests. Data are presented as mean ± SD.  
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Figure 29: Proteomics analysis of 4 KrasMUT samples (protein lysates of LLC, FULA1 cell lines / murine 
flank tumors established with LLC/FULA1) and 2 KrasWT protein lysates (PANO2 cell lines/ murine flank 
tumors established with PANO2. All samples were treated/untreated with deltarasin IC60 doses for 72 h. 
(A) Analytical strategy of the proteome analysis explained as Venn diagram. n = 3 for every sample. (B) 
Analysis revealed 2 proteins upregulated in KrasMUT cell lines after deltarasin induction while 
downregulated in deltarasin treated tumor samples (CSN9, CPT1A), and 1 protein upregulated in 
deltarasin treated KrasMUT tumor while downregulated in deltarasin treated KrasMUT cell lines (K1C16). 
Shown are fold changes in protein abundance ∆PE. (C) Kaplan-Meier analyses done on 
http://www.kmplot.com78, of lung cancer patients focusing on low and high expression of the genes of 
interest.  
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7. Discussion 
The KRAS oncogene, one of the most frequent mutated cancer drivers, is still not druggable, 
due to its multi-diverse signaling probabilities. We and others hypothesized that hyperactive 
KRAS controls tumor progression in a cell independent manner and is mainly visible in vivo, 
questioning cellular based assays to find new KRAS drugs. Additionally, we identified main 
interaction partners, the inflammatory mediators CCL2 and IL-1β. With this we have reason to 
propose clinical trials aiming to target CCL2, IL-1β, and respective receptors in KRAS-mutant 
tumors. 
For this piece of work, 30 human and murine cancer cell lines with diverse mutations and 
different preclinical KRAS agents were used, tested with various in vitro assays. In line with 
others we detected, that the oncogenicity of KRAS is much stronger in an in vivo surrounding. 
The genetic and pharmacologic KRAS inhibition against Kras/KRAS-mutant murine and 
human tumors was clearly measurable in vivo, while conventional in vitro studies failed. Using 
isogenic cell lines, we found a novel mutant Kras transcriptome signature including 
inflammatory mediators Ccl2 and Il1r1. Further research with transgenic mouse strains and 
adoptive bone marrow transfer experiments revealed a strong in vivo dependence to CCR2+ 
IL-1β-secreting myeloid cells and we prove that the KRAS inhibitor deltarasin functions to 
decrease Il1r1/IL1R1 expression in Kras/KRASMUT cancer cells. Additionally, the 
KRAS/CCL2/IL-1β signature shows an enrichment in human KRASMUT cancers.  
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Figure 30: Graphical summary of the proposed mechanism of in vivo limited KRAS dependency. KRAS 
mutant cancer cells secrete CCL2 and express IL1R1 in a higher fashion than their wildtype 
counterparts, thereby recruiting CCR2+ myeloid cells to the tumor environment, subsequently increasing 
IL-1β levels and activating a positive feedback loop of increased tumor cell proliferation and enhanced 
inflammatory signaling. Deltarasin can interfere in this loop as KRAS specific inhibitor, decreasing IL1R1 
expression and downregulating IL-1β signaling. 
 
 In vivo dependency of the KRAS oncogene  
The underlying finding that hyperactive KRAS is not influencing cancer cell lines in vitro in a 
consistent fashion, is based on variable cellular assays, tested with three different pre-clinical 
KRAS agents using a huge set of murine and human cell lines. Unfortunately, reliable and 
significant differences concerning KRAS mutation status were not detectable. Further in vivo 
experiments showing mutation specific tumor growth differences led to the conclusion that 
KRAS inhibition is largely examinable under in vivo conditions. Several points of evidence can 
be found in the literature, supporting that 2-D cell cultures are suboptimal for the study of KRAS 
addiction. Singh et al. created a “Ras dependency index” (RDI) to classify KRAS dependency 
by using various human pancreatic and lung cancer cell lines90. By using RNAi against KRAS 
they classified cancer cell lines according to their KRAS addiction and consequently created a 
gene expression signature revealing several synthetic lethality partners. These cell line 
rankings should be assessed with higher priority in future KRAS target identification and 
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validation. Another group discusses the issue that synthetic lethal interaction partners for 
KRAS can never be confirmed across different KRAS-mutant tumors. Under the title DRIVE 
(deep RNAi interrogation of viability effects in cancer), they launched a comprehensive screen 
using a lentiviral library consisting of > 150000 shRNAs checking 7,837 genes and 398 cancer 
cell lines. Their data highlights the possibility that no lethal interaction partner for KRAS can 
be found in vitro across commonly used KRAS tumor models91. Janes et al. published their 
findings about a new KRAS inhibitor, ARS-1620, with the same problematic of high differences 
between in vitro and in vivo models. In summary they and others observe less than 50% KRAS 
addiction of cancer cell lines outside a functioning tumor environment53. In the study conducted 
by Scholl et al. identifying STK11 as synthetic lethality partners, 25% of KRAS-independent 
cell lines did not respond to STK11 suppression55. Also, in the publication of Barbie et al., 20% 
of human KRASMUT cell lines did not respond to shRNA against TBK1 to decrease cell viability 
in vitro, additionally highlighting the problem of in vitro KRAS studies37. In this context, we 
compared effective preclinical drug concentrations of TKIs for lung cancer treatment, among 
others Erlotinib, Gefitinib, Ceritinib, Crizotinib, and Dabrafenib with respective in vitro drug 
concentrations of different preclinical KRAS inhibitors, all tested in monolayer cell cultures. 
Interestingly, there is a dissimilarity between these two groups (Fig.11D). Successfully FDA-
approved drugs inhibited cancer cell lines in nanomolar concentrations raising optimism for 
future clinical treatments. Instead, research with preclinical KRAS inhibitors showed efficacy 
from micromolar concentrations onwards, doses, which are clinically not promising (see 
supplementary reference list S8-S25). Until now, therapeutic intervention has not yielded any 
success, although KRAS plays this enormous role in human cancers92. The knowledge gained 
from others and us, of continual failures of KRAS drug development, shifts the focus on in vivo 
restricted mechanisms and its inherent answer to effective KRAS inhibition.  
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 Targeting inflammatory interaction in KRAS-driven tumorigenesis 
There is overwhelming evidence that KRAS-driven carcinogenesis is tightly correlated with 
tumor promoting inflammation. Activating mutations equip epithelial cells with the ability to 
survive and expand beyond cell intrinsic mechanism, exploiting cytokines that recruit 
inflammatory cells, and by this communicating strongly with the tumor environment. This cross-
talk can switch the inflammatory response from anti-tumorigenic to pro-tumorigenic. KRAS has 
the capability of changing the nature of the inflammasome, thereby modulating recruitment, 
activation, and differentiation of immune cells beyond cell-autonomous effects41,63,67. Indeed, 
organs which are forced to constantly resist negative inflammatory influences or chronic 
inflammatory diseases, likely develop tumors with high KRAS mutation burden30,68,89.   
 
Figure 31: Three cancer types harboring high KRAS mutation rates, lung, pancreas, and colon cancer, 
often arise through chronic inflammatory processes and diseases in theses organs30,68,89.  
 
Immune cells communicate via soluble mediators, cytokines, either produced by themselves 
or the surrounding cancer cells. A pioneering report showed how CXCL8 (IL-8), an angiogenic 
growth factor, is a transcriptional target of RAS proteins directing paracrine signaling to 
endothelial cells44. This raised the possibility of a specific role in KRAS-driven NSCLC, and IL-
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8 was proven to be upregulated in patient samples of KRAS mutated LADC93. Using a similar 
experimental strategy, Ancrile et al. identified IL-6 as paracrine signaling molecule of 
oncogenic RAS, promoting angiogenesis94. Later, researchers were able to pin down mutant 
KRAS as key regulator of IL-6 transcription followed by NF-κΒ activation and STAT3 
expression. The signal transducer and activator of transcription STAT3 is an important 
transcription factor for tumor growth and angiogenesis, as well as for development of the 
premalignant state of pancreatic cancer, the acinar-to-ductal metaplasia (ADM)95,96. Mutated 
KRAS is also shown to mediate T-cell recruitment and in turn producing high IL-22 levels, 
effecting STAT3 and AKT activation96. In 2005 Ji et al. developed the conditional KrasG12D 
mutant mouse in which the mutated allele is specifically expressed in CC10+ bronchiolar 
epithelial cells (club cells), and demonstrated the KRAS dependent chemokine production thus 
recruiting myeloid cells into the tumor97. Myeloid cells are studied intensively in context to 
oncogenic KRAS with specific focus on macrophages and neutrophils. Busch et al. were able 
to assign host immune cells histologically to either SCLC or LADC, showing a lymphocyte 
dominance in SCLC over myeloid cells (macrophages, neutrophils, and eosinophils) in 
LADC98. These cells infiltrate the KRAS mutant tumor helping it proliferate. They secrete 
inflammatory mediators which will certainly activate pro-tumorigenic pathways and further 
contribute to tumor invasiveness. Oncogenic KRAS is known to attract myeloid cells by 
releasing chemokines, such as CXCL1, CXCL2, and CXCL5 recruiting neutrophils, as well as 
CCL2, decoying CCR2+ macrophages41,99. Another molecule,  ICAM-1, was identified as 
macrophage chemoattractant secreted by KRAS expressing pancreatic cells, which in turn 
secrete tumor necrosis factors (TNFs) and matrix metalloproteinases (MMPs), well known 
cancer progressors100. This knowledge in mind we analyzed the transcriptome of a panel of 
KrasMUT and KrasWT cell lines. Surprisingly, the cell lines did cluster according to their Kras 
mutation status and not to their tissues of origin (Fig. 19A). Our murine Kras-specific gene set 
consisted of multiple inflammatory mediators proving KRAS dependence to the inflammatory 
tumor microenvironment. It was enriched in human KRASMUT cancers and was linked to poor 
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survival. Both GSEA and WikiPathways analysis showed some parallels to inflammatory 
response pathways, proving that the oncogene has proinflammatory functions. The use of 
syngeneic LADC mice models allowed us to focus on the innate immune response. Most of 
the murine cell lines used for allograft models were extracted from spontaneously in mice 
developed tumors or from carcinogen-models, from which cell lines were developed after 
carcinogen exposure, murine lung tumor development, extraction, cell culturing, and molecular 
profiling26,101. The allograft model has the advantage of an intact host immune system, which 
is missing in immunocompromised mice. For genetic variation we used two different wildtype 
mice for our studies, FVB and C57BL/6 mice. Additionally, Rag2-/- mice, deficient in T- and B-
cell differentiation, but expressing intact myeloid cells, were therefore used in this study to work 
with xenograft models102. The measurable drug effect tested in this mice strain supported our 
theory of an innate inflammatory response that potentiates KRAS inhibition.  
 CCL2/CCR2 and IL-1β/IL1R –new targets for KRAS mutant cancer? 
Two inflammatory molecules of our gene expression list are found in the literature with similar 
context, CCL2 and IL1R1. Both play a huge role in tumor development, MPE formation and 
are specifically upregulated in our KRAS-mutant cell lines (Fig. 19)36,41. Consequently, we 
validated both candidates of our KrasMUT signature on RNA and Protein level. We narrowed 
down the drug effectiveness to decrease expression of IL1R1 in KRAS-mutant tumor cells and 
thus stopping the receptivity to IL-1β. CCR2+ myeloid cells were stated as important key 
players in KRAS-mutant tumors and were proven to be mandatory for oncogenic KRAS 
dependence in vivo, also shown by their enrichment in tumor tissue (Fig. 21)36,41,43,79. This 
hypothesis was further supported by data from syngeneic mouse models of Ccr2 and Il1b gene 
knockdown, from BMT experiments with crucial myeloid Ccr2 reconstitution, and by xenograft 
experiments in Rag2-/- mice  (intact myeloid cells, but B- and T-cell function deficient) using 
human cancer cell lines102. Compared to effective deltarasin in FVB mice, slowing down tumor 
growth statistically, the drug lost its efficacy in Ccr2 knockdown strains completely and in parts 
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in Il1b knockdown strains. In summary, we were able to show how deltarasin functions to inhibit 
a mutant KRAS-initiated inflammatory loop of tumor-secreted CCL2 and myeloid-derived IL-
1β. The lesser effect in Il1b knockdown mice can be explained due to present IL-1α with 
redundant effects103. The chemokine CCL2 (MCP-1), produced from bone marrow, stroma and 
tumor, plays a huge role in guiding the infiltration of myeloid cells to the tumor 
microenvironment due to its chemoattractant function36,41,104,105. Ninety percent of its surface 
receptor CCR2 is expressed by monocytes and NK cells. The CCL2-CCR2 axis is a well-
studied subject concerning pro-tumorigenic function, cancer metastasis, migration, 
pathological inflammation, and angiogenesis. CCL2 and its receptor control and recruit 
monocytes from the bone marrow into the bloodstream to sites of inflammation and tumor 
environment. The chemokine can turn them in tumor associated macrophages (TAM). TAMs 
are limiting the effect of anti-tumorigenic immune responses, in favor of progression and 
chemoresistance106. The activation can increase expression of metalloproteinases like MMP2 
and MMP9 in cancer cells and thereby increase invasion and metastatic potential destroying 
healthy ECM. In breast, colon, and prostate cancer, CCL2  blockade with murine or humane 
neutralizing antibodies were highly effective in reducing tumor burden, macrophages 
infiltration, tumor associated vascularity, and metastasis105. In a breast cancer 
chemoresistance study of 2012 it was shown how CCR2+ myeloid cells contribute to 
resistance development to Doxorubicin and Cisplatin, well known chemotherapeutics. In Ccr2 
null host mice Doxorubicin effect was prolonged by inhibiting resistance development. They 
and others suggest treatment combination of chemotherapy with agents changing the 
inflammatory signaling, in particular CCR2 or CCL2 inhibitors107.  
Increased IL-1 levels have been connected to the pathogenesis of acute and chronic (i.e. 
atherosclerosis, rheumatoid arthritis) inflammatory diseases108. In cancer excessive IL-1 
concentrations are tumor growth promotors and poor prognostic factors for patients. Thereby, 
IL-1β and IL-1α play distinct and similar roles109. An important difference is IL-1β’s regulation 
by acute inflammatory signaling, while Il-1α is ubiquitous expressed and homeostatic present 
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within the cell108. Krelin et al. published their studies with different IL-1 knockout mice (IL-1α-/-, 
IL-1β-/-, IL-1α/β-/-, IL-1Ra-/-) and 3-methylcholanthrene (3-MCA), a strong carcinogen, in which 
they named IL-1β as main tumor progressor and potentiator of inflammatory response. In IL-
1β-/- and IL-1α/β-/- mice, tumor development was significantly slowed down after 3-MCA 
treatment compared to the other null mice (≥ 110 days)108,110. The tumor microenvironment 
derived interleukin can activate complex downstream signaling pathways in cancer cells, such 
as activation  of NF-kB, which induces transcription of inflammatory mediators like CCL2 and 
IL-1 itself,  and thereby tumor growth36,41. Agalioti et al. studied paracrine CCL2 signaling to 
CCR2+ myeloid cells (mononuclear and mast cells) in dependence to oncogenic KRAS. This 
progresses malignant pleural effusion by induction of vascular permeability and angiogenesis. 
It was druggable both with deltarasin and CCL2 neutralizing antibody41. Subsequently, CCR2+ 
myeloid cells secreted IL-1β, which was found to selectively elevate non-canonical ΙΚΚα-
mediated NF-κΒ activity, thereby enhancing tumor progression, MPE formation and drug 
resistance. The signaling culminates in enhanced CXCL1/PPBP expression which escalates 
tumor-associated inflammation. In this study, Marazioti et al. analyzed the origin of host IL-1β 
and eliminated the possibility of cancer cell producing IL-1β36. Both studies elucidate the 
mechanism of KRAS function to recruit immune cells to the tumor environment. Unfortunately, 
clinical trials of therapeutics like the anti-human CCL2 antibody carlumab (CNTO888) were 
disappointing by limited drug efficacy and tolerability. Still, CCL2 neutralizing antibodies yield 
good preclinical results in cancer models, and the axis seems to be a relevant target in our 
findings104,105,111–114. In addition to CCL2/CCR2, blockade of IL-1β/IL1R1 in cancer therapy is a 
promising and well-studied research subject115. Targeting IL-1β with the monoclonal antibody 
canakinumab, which is in clinical trials, raises enthusiasm in cancer therapy. In this context, 
Ridker et al. published an exploratory evaluation of the CANTOS trial (Canakinumab anti-
inflammatory thrombosis outcome study). This study included 10061 patients with 
atherosclerosis, 129 of which had lung cancer115,116. They confirmed as second aim, if low (50 
mg), medium (150 mg), or high (300 mg)-dose canakinumab (sc every three months) might 
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change cancer frequency. Treatment with the high-dose canakinumab decreased the total 
cancer mortality significantly (n = 77) by 51%, which was astonishing. The incidence of lung 
cancer decreased by 39% in the medium-dose and in the high-dose group by 67%, while the 
mortality of lung cancer decreased by 77%. The KRAS mutation status of these patients would 
be of tremendous value to analyze and answer the question of context. Our results suggest 
canakinumab as possible selective anti-KRAS drug. These research findings together with the 
present work, highlight CCL2, IL-1β, and their receptors as important inflammatory addiction 
partners, and make them highly interesting in clinical context.  
 Other synthetical lethality partners of KRAS  
The KrasMUT gene expression list of our cell line panel includes other synthetic lethality partners 
of KRAS. Besides Kras, Ccl2, and Il1r1, the signature contains signal transducers Gpr149, 
Rassf8, and Ranbp3l, inflammatory mediators Cxcl1, Ccl7, and Casp3, cell surface receptors 
Ttk and Pdgfra, and tumor suppressors and cell cycle genes Plag1, Cdca5, Fanca, Hist2h3c2, 
and Gmnn, among others. CXCL1 is proven to be a downstream effector of mutant KRAS. 
KRAS mutant tumor cells activate non-canonical NF-ĸB pathway via IKKα in response to high 
concentration of host derived IL-1β. This leads to enhanced transcription of this chemokine 
and subsequent progression of malignant pleural effusion36. CXCL1 is also correlated with 
lymph node and peritoneal metastasis, and lymphatic venous malignant invasion117. Geminin 
DNA Replication Inhibitor (Gmnn) was recently identified as a tumor suppressor in colon and 
lung cancer118. The cysteine protease Casp3 is not just an apoptosis effector caspase, but also 
central signal molecule of rapid tumor-repopulation and radiotherapy resistance induced via 
apoptosis119. Caspase-3 can thereby activate calcium independent phospholipase A2 (iPLA2) 
which further activates prostaglandin E2 (PGE2) synthesis. This increases stem cell 
proliferation and leads to compensatory tumor repopulation. Apoptosis can thereby actively 
promote cell survival of the surrounding cells by the dual role of the Caspase-3. It was shown, 
that high expression of Caspase-3 is linked to shorter survival rates in cancer patient samples 
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making it a negative prognostic biomarker119. The induced inflammatory response mechanism 
via deltarasin could mask these survival signals of this compensatory proliferation pathway 
(Fig. 30). In in vitro experiments this non-cell-autonomous survival effect is not existing, 
therefore KRAS inhibitors are not specifically effective. Nevertheless, results with the caspase 
inhibitor Z-DEVD-FMK did not show an effect, but since the inhibitor has an overall caspase 
inhibition effect, pro-survival effects could be stronger and targeting apoptosis pathways needs 
to be carefully evaluated120. The inhibitor of apoptosis (IAP) antagonist BV6 in combination 
with deltarasin showed promising effects. The drug, a SMAC-mimetic (SMAC, second 
mitochondrial derived activator of caspases; human natural IAP antagonist) targets IAP 
proteins, which control the cleavage and activation of Caspase-3121. Inhibition of IAP proteins 
also affect downregulation of NF-kB and MAPK pathways, highly supportive effects to inhibit 
tumor growth, especially for KRAS- mutant cancer types. Thereby the inflammatory response 
via cytokine induction and proinflammatory gene regulation is decreased by the IAP inhibitor. 
Since IAP proteins demonstrate a good target for cancer treatments several antagonists have 
entered clinical trials122. Our proteomics analysis revealed another candidate which was higher 
expressed in KRAS-mutant cell lines and lower in KRAS-mutant tumor samples, both 
expression levels valuated after longer deltarasin treatment, the COP9 signalosome complex 
subunit 9 (CSN9). The complex is strongly involved in innate immune signaling and 
proteasome activation, as well as prediction of better survival if lower expressed. By controlling 
the ubiquitin-proteasome system (UPS) it can thereby indirectly regulate tumor suppressors 
like p53, transcription factors, or oncogenes. The clinical value of this axis is proven by the use 
of proteasome inhibitors such as bortezomib. That makes COP9 as regulatory element of the 
UPS therapeutically interesting in the treatment of cancer123,124.  
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Figure 32: A compensatory proliferation mechanism activated through KRAS-mediated high expression 
of caspase-3. Activation of caspase-3 will increase PGE2 synthesis via PLA2 thereby activation a tumor-
specific pro-survival mechanism of compensatory proliferation. This can be inhibited via deltarasin in 
vivo by recruitment of inflammatory cells to the tumor microenvironment. PTGER2, prostaglandin E 
receptor 2; PGE2, prostaglandin E2; PLA2, Phospholipase A2. 
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 Conclusion  
In summary, we show that KRASMUT cancer cells act highly diverse depending on the given 
surrounding. Our work is in line with others claiming a change in drug development process 
for finding KRAS inhibitors. We identify an underlying mechanism of KRAS action beyond 
intrinsic cell-autonomous signaling and show that cancer with oncogenic KRAS overexpresses 
CCL2 and IL1R1 to recruit CCR2+ IL-1β-expressing myeloid cells to feed an inflammatory 
signaling loop. In our studies using deltarasin we found an underlying mechanism of action, 
which is targeting IL1R1 expression. In addition, we were able to show the relation of murine 
based research to human patient data. The KRAS/CCL2/IL-1β axis is essential for KRAS-
dependent tumor growth and blockade and can be used in the future to design clinical trials 
for KRAS mutant cancers.  
New findings:  
 Extensive proof for the discrepancy between in vitro and in vivo findings related to 
KRAS inhibition.  
 Identification and validation of the mechanism for the in vivo-restricted efficacy of KRAS 
inhibitors. 
 Determination of the requirement for the KRAS/CCL2/IL-1β axis for successful KRAS 
inhibition. 
 Proof-of-concept human data supporting the existence of the proposed mechanism in 
human cancer.  
 A novel KRAS signature containing candidate KRAS addiction partners for future 
research
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9. Abbreviations  
 List of acronyms and abbreviations  
AA amino acid 
ABTS 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt 
ATP   adenosine triphosphate 
BM   bone marrow 
BMT   bone marrow transplantation  
BSA   bovine serum albumin 
BrdU    bromodeoxyuridine, 5-bromo-2'-deoxyuridine 
CRC   colorectal cancer 
DMEM   dulbecco’s modified eagle medium 
DMSO   dimethylsulfoxide 
DRIVE   deep RNAi interrogation of viability effects in cancer 
e.g.   exempli gratia, for example 
ELISA   enzyme-linked immunosorbent assay 
GdmCL  guanidine hydrochloride 
GSEA   gene set enrichment analysis 
GTP   guanosine triphosphate  
HR   hazard ratio 
ip   intraperitoneal  
iv   intravenous 
IU   international units 
Kras/KRASMUT Kras/KRAS mutant 
Kras/KRASWT  Kras/KRAS wildtype  
LADC   lung adenocarcinoma 
LC   lung cancer 
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ml   milliliter  
MPE   malignant pleural effusion 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MTS     3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) 
NAD/NADH nicotinamide adenine dinucleotide  
NADP/NADPH nicotinamide adenine dinucleotide phosphate 
nm   nanometer 
NSCLC   non-small-cell lung cancer 
PBS   phosphate-buffered saline 
PDAC   pancreatic ductal adenocarcinoma 
PMS   5-methylphenazinium methyl sulfate 
RIPA   radioimmunoprecipitation assay 
RPMI   roswell park memorial institute 
sc   subcutan 
SCID mice  Severe combined immunodeficient mice 
SCLC   small-cell lung cancer 
SDS   sodiumdodecylsulfate  
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
sh   short hairpin 
SQCLC  squamous cell lung cancer  
TAE   Tris-acetate-EDTA 
TCGA   the cancer genome atlas 
TKI   tyrosine-kinase-inhibitor  
WT   wild-type  
WST-8 tetrazolium-1[2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulphophenyl)-2H-teterazolium 
µg   microgramm 
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 List of gene/protein description 
AKT Protein Kinase B 
ALK  Anaplastic Lymphoma Receptor Tyrosine Kinase  
ARID1A  AT-Rich Interaction Domain 1A 
BAD   Bcl-2-Antagonist of Cell Death 
BCL-2   B-cell Lymphoma 2 
BRAF    B-Raf Proto-Oncogene 
CCL2   C-C motif Chemokine Ligand 2 
CCR2   C-C motif Chemokine Receptor 2 
CDK4   Cyclin Dependent Kinase 4 
CDKN2A   Cyclin Dependent Kinase Inhibitor 2A 
CXCL1  Chemokine (C-X-C motif) Ligand 1 
CXCR1  Chemokine (C-X-C motif) Receptor 1 
EGFR   Epidermal Growth Factor Receptor 
ERK   Extracellular-Signal-Regulated Kinase  
FT   Farnesyltransferase 
GAP   GTPase Activating Protein  
GAPDH   Glyceraldehyde 3-Phosphate Dehydrogenase 
GEF   Guanine Nucleotide Exchange Factor  
GGT   Geranylgeranytransferase 
Gmnn   Geminin DNA Replication Inhibitor 
GRB2   Growth Factor Receptor Bound 2 
HRAS   HRas Proto-Oncogene; Harvey Rat Sarcoma (historical name) 
HRP   Horseradish Peroxidase  
ICMT   Isoprenylcysteine Carboxylmethyltransferase 
IKKα/β  IκB Kinase alpha/beta  
IκB    NF-kappa-B inhibitor alpha 
IL1B   Interleukin 1 beta 
IL1R   Interleukin 1 Receptor  
iPLA2   Calcium Independent Phospholipase A2 
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KEAP    Kelch Like ECH Associated Protein 1 
KRAS   KRAS proto-oncogene GTPase; Kirsten Rat Sarcoma (historical name) 
LDH   Lactate Dehydrogenase 
MAPK   Mitogen-Activated Protein Kinase  
MCP-1  Monocyte Chemotactic Protein 1 
MEK   Mitogen-activated Protein Kinase Kinase (MAPKK) 
MET    MET Proto-Oncogene 
mTOR   Mammalian Target of Rapamycin 
NF-ĸB Nuclear Factor ĸ light-chain Enhancer of Activated B Cells  
NF1   Neurofibromin-1 
NRAS   NRAS Proto-Oncogene; Neuroblastoma Rat Sarcoma (historical name) 
PD-1   Programmed Cell Death 1 
PD-L1   Programmed Cell Death-Ligand 1 
PDEδ   Phosphodiesterase δ 
PDK1   Pyruvate Dehydrogenase Kinase 1 
PIK3CA  Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit 
Alpha 
PI3K   Phosphatidylinositol 3-Kinase 
PLK1   Polo Like Kinase 1 
PTEN   Phosphatase and Tensin Homolog 
p-ERK   Phospho- Extracellular-Signal Regulated Kinase 
RAG2   Recombination Activating Gene 2 
RAF   Rapidly Accelerated Fibrosarcoma 
RAS   Ras Sarcoma  
RCE1   Ras-Converting Enzyme 1 
RTK   Receptor Tyrosine Kinase  
ROS1    ROS Proto-Oncogene 1 
SHC   SHC Adaptor Protein  
SH3   Sarcoma Homology 3 
SMAC   Second Mitochondrial Derived Activator of Caspases 
SMARCA4  SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of 
Chromatin, Subfamily A, Member 4 
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SOS   Son of Sevenless 
STK11  Serine/Threonine Kinase 11 
TBK1    TANK Binding Kinase 1 
t-ERK   Total- Extracellular-Signal Regulated Kinase 
TP53    Tumor Protein P53 
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12. Appendix 
  Supplementary figures 
 
Supplementary figure. S1: Response of KRAS-mutant cancer cell lines to deltarasin IC60 concentrations 
for 72 hours and analysis by colony formation assay. Diverse mouse (A; KrasMUT: LLC, FULA1; KrasWT: 
B16F10, PANO2) and human (B; KRASMUT: A549, H460; KRASWT: EKVX, H3122) tumor cell lines were 
evaluated for colony formation (n = 3/ data-point). Data presented as mean ± SD. P, overall probability 
by one-way ANOVA. ns, *, **, ***, and ****: P > 0.05, P < 0.05, P < 0.01, P < 0.001, and P < 0.0001 
respectively, for the presented comparisons by Bonferroni post-tests. Shown are total number of 
colonies formed (A, B), plating efficiency of 300 cells/well at experiment start (C, D), and survival fraction 
of single cells given as ratio treatment/ no treatment (E, F). Figure modified from Arendt et al.80.  
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Supplementary figure. S2: Full pictures of Western blot analysis for figure 12D. (A) Murine cell line 
protein extracts of untreated and treated samples with deltarasin (72 hours; IC60). Left, p-ERK, right t-
ERK; below, belonging GAPDH lanes. (B) Human cell line protein extracts of untreated and treated 
samples with deltarasin (72 hours; IC60). Left, p-ERK, right t-ERK; below, belonging GAPDH lanes. Black 
boxes highlight areas of the blots shown in main figure. Figure modified from Arendt et al.80.  
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Supplementary figure. S3: Vector maps of GFP-KrasG12C plasmid. Overexpression of mutant KRAS (A) 
and control plasmid with only GFP (B). Vector maps from http://www.addgene.com. Plasmids are 
purchased through the Addgene website.  
A 
B 
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Supplementary figure. S4: Transduction of pKrasG12C in human cell lines H3122 and EKVX was validated 
via immunofluorescence. The pKrasG12C plasmid includes GFP and puromycin resistance genes. 
Representative microscopy images of pC control or pKrasG12C transfected cell lines. Left, brightfield 
images; middle, green fluorescent images; right, merged images. A confocal microscope LCI510 (Zeiss; 
Jena, Germany) was used. Figure modified from Arendt et al.80.  
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Supplementary figure. S5: Full pictures of Western blot analysis for figure 15D. Murine and human cell 
line protein extracts with or without Kras/KRAS genetic modification were used for this experiment. Left, 
p-ERK, right, t-ERK; below, belonging GAPDH lanes. Black boxes are the area of the blots presented 
in the main figure. Figure modified from Arendt et al.80.  
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Supplementary figure. S6: Detailed overview of the analysis of the transcriptomics data of murine cell 
lines. MC38 was filtered manually since data was produced on a different GeneChip (Mouse Gene 1.0 
ST array). All the other samples were hybridized to GeneChip MoGene 2.0 ST arrays (Affymetrix, St. 
Clara, CA). For analysis TAC software was used and differential gene expression was filtered for a final 
mutant Kras-specific gene list. 
 
1408 genes
significantly (P < 0.05) over- or under-represented in 
KRAS-mutant cell lines (LLC, AE17, MC38, FULA1) over both KRAS-WT cell lines (B16F10, B16F10 
pC, PANO2, CULA) and benign samples (TEC, BMDM, BMMC, Lungs)
3432 genes
responsive (ΔGE > 1.4) to both
KRAS-shRNA in KRAS-mutant cell lines (LLC and AE17) and to  KRAS-overexpression in KRAS-WT 
cell lines (B16F10 and PANO2) 
204 common 
genes
116 genes
over-represented in KRAS-mutant cells, silenced 
by KRAS-shRNA, and induced by KRAS-
overexpression 33 genes
under-represented in KRAS-mutant cells, induced by 
KRAS-shRNA, and suppressed by KRAS-overexpression
55 genes
with equivocal 
changes
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genes
32 genes
over-represented in KRAS-mutant cells, silenced 
by KRAS-shRNA, and induced by KRAS-
overexpression 10 genes
under-represented in KRAS-mutant cells, induced by 
KRAS-shRNA, and suppressed by KRAS-overexpression
128 genes
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changes
Filtering
MC38
manual
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Supplementary figure. S7: Immunofluorescence images of tumor tissue sections. Human and murine 
tumors were established through sc injection of 106 tumor cells (FULA1, PANO2; H460, EKVX) and 
extracted from these xenograft flank models (FVB, C57BL/6; Rag2-/- mice). Antibody control stainings 
for IL-1β (IgG2a Alexa Fluor488) and CCR2 (Alexa Fluor647). Bar = 50 µm. 
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 Supplementary tables  
Supplementary table S1: Deltarasin effects tested in murine and human cancer cell lines. 
Originating 
oganism Cell line Tissue origin 
KRAS 
mutation 
IC50 (μM, 
mean±SD)a n 
C57BL/6 mouse LLC Lewis lung carcinoma G12C 1.46 ± 0.16 3 
C57BL/6 mouse MC38 Colon adenocarcinoma G13R 1.23 ± 0.22 3 
C57BL/6 mouse AE17 Malignant pleural mesothelioma G12C 1.61 ± 0.13 3 
FVB mouse FULA Urethane-induced lung adenocarcinoma Q61R 2.10 ± 0.06 3 
C57BL/6 mouse B16F10 Malignant skin melanoma None 2.41 ± 0.37 3 
C57BL/6 mouse PANO2 Pancreatic adenocarcinoma None 2.10 ± 0.49 4 
C57BL/6 mouse CULA Urethane-induced lung adenocarcinoma None 1.59 ± 0.29 3 
Human A549 Lung adenocarcinoma G12S 6.90 ± 0.96 3 
Human H460 Lung large cell carcinoma Q61H 5.27 ± 2.24 3 
Human H358 NSCLC G12C 3.27 ±1.10 3 
Human H358M Bronchiolo-alveolar carcinoma G12D 3.67 ± 1.70 3 
Human H1944 NSCLC G13D 6.93 ± 1.32 3 
Human H520 Squamous cell carcinoma None 1.67 ± 0.06 3 
Human EKVX Lung adenocarcinoma None 4.22 ± 2.41 3 
Human H1299 NSCLC None 5.40 ± 1.81 3 
Human H3122 NSCLC None 4.73 ± 1.38 3 
a IC50, 50% inhibitory concentration by WST-8 assay (Bimake); SD, standard deviation; n, sample 
size; NSCLC, non-small cell lung cancer. 
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Supplementary table S2: AA12 effects tested in murine and human cancer cell lines.  
Originating 
oganism Cell line Tissue origin 
KRAS 
mutation 
IC50 (μM, 
mean±SD)a n 
C57BL/6 mouse LLC Lewis lung carcinoma G12C 22.69 ± 7.95  3 
C57BL/6 mouse MC38 Colon adenocarcinoma G13R 4.59 ± 2.45  2 
C57BL/6 mouse AE17 Malignant pleural mesothelioma G12C 3.06 ± 1.39 2 
FVB mouse FULA1 Urethane-induced lung adenocarcinoma Q61R 4.97 ± 2.28 2 
C57BL/6 mouse PANO2 Pancreatic adenocarcinoma None 20.85 ± 5.11 2 
Human A549 Lung adenocarcinoma G12S 49.30 ± 24.31 3 
Human HOP-62 Lung adenocarcinoma G12C   3 
Human H358 NSCLC G12C 27.85 ± 4.41 2 
Human H3122 NSCLC None 24.24 ± 11.41 3 
a IC50, 50% inhibitory concentration by WST-8 assay (Bimake); SD, standard deviation; n, sample 
size; NSCLC, non-small cell lung cancer. 
 
 
  
12 Appendix 
131 
 
Supplementary table S3: Cysmethynil effects tested in murine and human cancer cell lines.  
Originating 
oganism Cell line Tissue origin 
KRAS 
mutation 
IC50 (μM, 
mean±SD)a n 
C57BL/6 mouse LLC Lewis lung carcinoma G12C 22.11 ± 2.19 2 
C57BL/6 mouse MC38 Colon adenocarcinoma G13R 18.13 ± 9.92 2 
C57BL/6 mouse AE17 Malignant pleural mesothelioma G12C 17.62 ± 3.57 3 
FVB mouse FULA1 Urethane-induced lung adenocarcinoma Q61R 27.37 ± 7.78 2 
C57BL/6 mouse B16F10 Malignant skin melanoma None 19.61 ± 13.27 3 
C57BL/6 mouse PANO2 Pancreatic adenocarcinoma None 16.92 ± 17.22 2 
Human A549 Lung adenocarcinoma G12S 30.84 ± 9.10 3 
Human H358 NSCLC G12C 28.32 ± 6.57 3 
Human EKVX Lung adenocarcinoma None 30.05 ± 5.66 3 
Human H3122 NSCLC None 10.95 ± 3.77 3 
a IC50, 50% inhibitory concentration by WST-8 assay (Biomake); SD, standard deviation; n, sample 
size; NSCLC, non-small cell lung cancer. 
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Supplementary table S4: Deltarasin in combination with IC25 BV6 (murine: 3 µM, human: 6.5 µM) effects 
tested in murine and human cancer cell lines. 
Originating 
oganism Cellline Tissue origin KRAS mutation 
IC50 (μM, 
mean±SD)a n 
C57BL/6 mouse LLC Lewis lung carcinoma G12C 0.004 ± 0.01 2 
FVB mouse FULA1 
Urethane-induced 
lung 
adenocarcinoma 
Q61R 0.25 ± 0.07 2 
C57BL/6 mouse B16F10 Malignant skin melanoma None 0.2 ± 0.14 2 
C57BL/6 mouse PANO2 Pancreatic adenocarcinoma None 0.35 ± 0.07 2 
Human A549 Lung adenocarcinoma G12S 0.03 ± 0.01 2 
Human H460 Lung large cell carcinoma Q61H 0.01 ± 0.003 2 
Human EKVX Lung adenocarcinoma None 1.31 ± 0.14 2 
Human H3122 NSCLC None 0.31 ± 0.02 2 
a IC50, 50% inhibitory concentration by WST-8 assay (Bimake); SD, standard deviation; n, sample 
size; NSCLC, non-small cell lung cancer. 
 
  
12 Appendix 
133 
 
Supplementary table S5: Deltarasin in combination with IC25 Z-DEVD-FMK (murine: 12 µM, human: 22 
µM) effects tested in murine and human cancer cell lines. 
Originating 
oganism Cell line Tissue origin 
KRAS 
mutation 
IC50 (μM, 
mean±SD)a n 
C57BL/6 mouse LLC Lewis lung carcinoma G12C 2.86 ± 0.68 2 
FVB mouse FULA1 Urethane-induced lung adenocarcinoma Q61R 2.61 ± 0.58 2 
C57BL/6 mouse B16F10 Malignant skin melanoma None 0.65 ± 0.49 2 
C57BL/6 mouse PANO2 Pancreatic adenocarcinoma None 6.95 ± 2.05 2 
Human A549 Lung adenocarcinoma G12S 2.45 ± 0.78 2 
Human H460 Lung large cell carcinoma Q61H 2.55 ± 0.77 2 
Human EKVX Lung adenocarcinoma None 3.05 ± 0.21 2 
Human H3122 NSCLC None 2.99 ± 0.69 2 
a IC50, 50% inhibitory concentration by WST-8 assay (Bimakel); SD, standard deviation; n, sample 
size; NSCLC, non-small cell lung cancer. 
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Supplementary table S6: Microarray analysis was performed and created a 42-gene mutant Kras 
signature after analysis of significant genes (P < 0.05 by unpaired ANOVA with bonferroni post-tests). 
For identification, Kras-mutant tumor cells compared with Kras-wild-type tumor cells and benign cells 
and tissues were tested, as well as >30% response to modulation of Kras expression five tumor cell line 
doublets tested (AE17, LLC, and MC38 cells expressing shC versus shKras and B16F10 and PANO2 
cells expressing pC versus pKrasG12C). Table modified from Arendt et al.80.   
Gene Symbol Description KrasWTa KrasMUTb % 
KrasRc 
Ccl2 chemokine (C-C motif) ligand 2 0.82 37.79 56.29 
Ranbp3l RAN binding protein 3-like 0.93 35.26 78.33 
Il1r1 interleukin 1 receptor, type I 2.39 25.63 36.71 
Gpr149 G protein-coupled receptor 149 0.80 22.94 55.68 
Cfap69 cilia and flagella associated protein 69 4.50 20.11 40.29 
Ccl7 chemokine (C-C motif) ligand 7 0.96 16.11 50.14 
2810417H13Rik RIKEN cDNA 2810417H13 gene 11.39 12.64 42.33 
Pdgfra platelet derived growth factor receptor α 1.89 12.38 41.60 
Casp3 caspase 3 4.20 10.48 30.74 
Ttk Ttk protein kinase 7.94 9.58 45.13 
Kif2c kinesin family member 2C 5.98 7.78 45.06 
Fanca Fanconi anemia, complementation group A 4.00 5.58 46.78 
Cdca5 cell division cycle associated 5 3.56 5.43 47.15 
Rassf8 Ras association (RalGDS/AF-6) domain family (N-terminal) 
member 8 
2.46 5.35 32.08 
Hist2h3c2 histone cluster 2, H3c2 1.20 4.69 38.87 
Plag1 pleiomorphic adenoma gene 1 0.78 4.53 53.15 
Nadk2 NAD kinase 2, mitochondrial 1.58 4.50 50.89 
Oaf OAF homolog (Drosophila) 2.39 4.23 31.03 
Cxcl1 chemokine (C-X-C motif) ligand 1 1.56 4.23 73.09 
Mmd monocyte to macrophage differentiation-associated 2.93 4.06 35.92 
Csgalnact1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 0.74 3.97 50.96 
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Clybl citrate lyase beta like 1.72 3.76 42.33 
Zfp334 zinc finger protein 334 1.04 3.68 58.59 
Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 2.08 2.60 39.71 
Palb2 partner and localizer of BRCA2 2.39 2.57 30.55 
Kcnab3 potassium voltage-gated channel, shaker-related subfamily, 
beta member 3 
1.25 2.55 49.23 
Mcts2 malignant T cell amplified sequence 2 1.45 2.36 30.65 
Pcnxl4 pecanex-like 4 (Drosophila) 1.38 2.19 39.54 
Gmnn geminin 1.39 2.04 34.57 
9530077C05Rik RIKEN cDNA 9530077C05 gene 1.17 1.88 30.46 
Poc1a POC1 centriolar protein homolog A 1.46 1.68 36.71 
Dhx40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 1.28 1.67 31.03 
Pde8a phosphodiesterase 8A 1.54 0.23 -181.67 
mt-Tt mitochondriallyencoded tRNA theonine 0.78 0.22 -95.34 
Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 0.60 0.20 -96.43 
Anxa6 annexin A6 0.69 0.19 -76.05 
mt-Te mitochondrially encoded tRNA glutamic acid 0.33 0.16 -49.69 
mt-Ty mitochondriallyencoded tRNA tyrosine 0.22 0.15 -77.77 
Bmyc brain expressed myelocytomatosis oncogene 1.42 0.15 -71.71 
Gm2a GM2 ganglioside activator protein 0.40 0.12 -70.05 
Smpdl3a sphingomyelin phosphodiesterase, acid-like 3A 1.21 0.11 -123.77 
mt-Tn mitochondriallyencoded tRNA asparagine 0.33 0.11 -105.91 
a Normalized mRNA expression levels of Kras-wild-type (WT) cell lines (B16F10, B16F10 pC, 
CULA, and PANO2) presented as ratios to expression of benign cells (bone marrow-derived 
macrophages BMDM and mast cells BMMC, tracheal epithelial cells TEC) and lungs (n = 4/group). 
b Normalized mRNA expression levels of Kras-mutant (MUT) cell lines (AE17, FULA1, LLC, and 
MC38) presented as ratios to expression of benign cells (BMDM, BMMC, and TEC) and lungs (n = 
4/group). 
c Percentile mean response (R) of mRNA expression to Kras modulation, including Kras silencing 
of Kras-mutant cell lines (AE17, LLC, and MC38) and overexpression of mutant KrasG12C plasmid in 
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Kras-wildtype cells (B16F10 and PANO2). Positive responses specify suppression by Kras silencing 
and induction by overexpression of mutant KrasG12C plasmid. Negative responses specify induction by 
Kras silencing and suppression by overexpression of mutant KrasG12C plasmid.  
LLC, C57BL/6 Lewis lung carcinoma; MC38, C57BL/6 colon adenocarcinoma; AE17, C57BL/6 
malignant pleural mesothelioma; FULA, FVB urethane-induced lung adenocarcinoma; B16F10, 
C57BL/6 malignant skin melanoma; PANO2, C57BL/6 pancreatic adenocarcinoma; CULA, C57BL/6 
urethane-induced lung adenocarcinoma. 
 Supplementary list: Hallmark gene set, Broad institute86 
‒ HALLMARK_ADIPOGENESIS 
‒ HALLMARK_ALLOGRAFT_REJECTION 
‒ HALLMARK_ANDROGEN_RESPONSE 
‒ HALLMARK_ANGIOGENESIS 
‒ HALLMARK_APICAL_JUNCTION 
‒ HALLMARK_APICAL_SURFACE 
‒ HALLMARK_APOPTOSIS 
‒ HALLMARK_BILE_ACID_METABOLISM 
‒ HALLMARK_CHOLESTEROL_HOMEOSTASIS 
‒ HALLMARK_COAGULATION 
‒ HALLMARK_COMPLEMENT 
‒ HALLMARK_DNA_REPAIR 
‒ HALLMARK_E2F_TARGETS 
‒ HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 
‒ HALLMARK_ESTROGEN_RESPONSE_EARLY 
‒ HALLMARK_ESTROGEN_RESPONSE_LATE 
‒ HALLMARK_FATTY_ACID_METABOLISM 
‒ HALLMARK_G2M_CHECKPOINT 
‒ HALLMARK_GLYCOLYSIS 
‒ HALLMARK_HEDGEHOG_SIGNALING 
‒ HALLMARK_HEME_METABOLISM 
‒ HALLMARK_HYPOXIA 
‒ HALLMARK_IL2_STAT5_SIGNALING 
‒ HALLMARK_IL6_JAK_STAT3_SIGNALING 
‒ HALLMARK_INFLAMMATORY_RESPONSE 
‒ HALLMARK_INTERFERON_ALPHA_RESPONSE 
‒ HALLMARK_INTERFERON_GAMMA_RESPONSE 
‒ HALLMARK_KRAS_SIGNALING_DN 
‒ HALLMARK_KRAS_SIGNALING_UP 
‒ HALLMARK_MITOTIC_SPINDLE 
‒ HALLMARK_MTORC1_SIGNALING 
‒ HALLMARK_MYC_TARGETS_V1 
‒ HALLMARK_MYC_TARGETS_V2 
‒ HALLMARK_MYOGENESIS 
‒ HALLMARK_NOTCH_SIGNALING 
‒ HALLMARK_OXIDATIVE_PHOSPHORYLATION 
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‒ HALLMARK_P53_PATHWAY 
‒ HALLMARK_PANCREAS_BETA_CELLS 
‒ HALLMARK_PEROXISOME 
‒ HALLMARK_PI3K_AKT_MTOR_SIGNALING 
‒ HALLMARK_PROTEIN_SECRETION 
‒ HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 
‒ HALLMARK_SPERMATOGENESIS 
‒ HALLMARK_TGF_BETA_SIGNALING 
‒ HALLMARK_TNFA_SIGNALING_VIA_NFKB 
‒ HALLMARK_UNFOLDED_PROTEIN_RESPONSE 
‒ HALLMARK_UV_RESPONSE_DN 
‒ HALLMARK_UV_RESPONSE_UP 
‒ HALLMARK_WNT_BETA_CATENIN_SIGNALING 
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